

EPA-560/6-75-004

**NATIONAL CONFERENCE
ON
POLYCHLORINATED BIPHENYLS
(NOVEMBER 19-21, 1975, CHICAGO, ILLINOIS)**



**Sponsored by: Environmental Protection Agency
in cooperation with:**

**Department of Agriculture
Council on Environmental Quality
Department of Health,
Education and Welfare
Department of the Interior**

**CONFERENCE PROCEEDINGS
ENVIRONMENTAL PROTECTION AGENCY
OFFICE OF TOXIC SUBSTANCES
WASHINGTON, D.C. 20460**

MARCH 1976

NPC00026586

753923

Conference Proceedings

**NATIONAL CONFERENCE ON
POLYCHLORINATED BIPHENYLS**

(November 1975, Chicago, Illinois)

Sponsored by
ENVIRONMENTAL PROTECTION AGENCY

in cooperation with
**DEPARTMENT OF AGRICULTURE
COUNCIL ON ENVIRONMENTAL QUALITY
DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
DEPARTMENT OF THE INTERIOR**

General Chairman
John L. Buckley, Consultant
Office of Research and Development
Environmental Protection Agency

Project Officer
Thomas E. Kopp
Office of Toxic Substances
Environmental Protection Agency

Conference Coordinator and Compiler
Franklin A. Ayer

CONTRACT NO. 68-01-2928

Prepared for
**ENVIRONMENTAL PROTECTION AGENCY
OFFICE OF TOXIC SUBSTANCES
WASHINGTON, D.C. 20460**

March 1976

NPC00026587

753924

This report has been reviewed by the Environmental Protection Agency and approved for publication. Approval does not signify that the contents necessarily reflect the views and policies of the Agency, nor does mention of trade names or commercial products constitute endorsement or recommendation for use.

ii

NPC00026588

753925

FOREWORD

The proceedings for the "National Conference on Polychlorinated Biphenyls" is the fourth report submitted under Contract No. 68-91-2828 to the Office of Toxic Substances for the Environmental Protection Agency. The three previous proceedings submitted under this contract dealt with Environmental Aspects of Chemical Use in Rubber, Well-Drilling, and Printing Operations. The PCB Conference was held at the Pick-Congress Hotel, Chicago, Illinois, on November 19-21, 1975.

The objectives of this conference were to bring together the latest data and best available expertise to help clarify the problems associated with the manufacture, use, and disposal of PCB's; to assess the effectiveness of steps taken to reduce the problems associated with PCB's; to provide a platform for interested parties to present previously neglected data concerning PCB's; and to help clarify the feasibility and complications of steps to reduce the problems associated with PCB's.

Dr. John L. Buckley, Consultant, Office of Research and Development, Environmental Protection Agency, Washington, D.C., was the General Chairman of the conference.

Mr. Thomas E. Kopp, Office of Toxic Substances, Environmental Protection Agency, Washington, D.C., was the Technical Coordinator of the conference.

Mr. Karl E. Bremer, Surveillance and Analysis Division, Region V, Environmental Protection Agency, Chicago, Illinois, was site coordinator and facilitator.

Mr. Franklin A. Ayer, Manager, Technology and Resource Management Department, Research Triangle Institute, Research Triangle Park, N.C., was the Conference Coordinator and Compiler of the proceedings.

ACKNOWLEDGMENTS

The National Conference on Polychlorinated Biphenyls owes its success to many, many people--to the organizers who arranged and accomplished such a massive undertaking, to the program chairmen and speakers who contributed so much insight and information, and most importantly, to the attendees whose interest and response made it all so worthwhile.

My special thanks to the Honorable Russell Train and the Honorable Nathaniel Reed for their supportive remarks at the Conference. Also, special thanks go to Mr. Francis Mayo, Director of EPA's Region V, Chicago; Mr. Karl Bremer of his staff; and Mr. Thomas Kopp of the Office of Toxic Substances for their superlative organizational work.

In extending appreciation to one and all, I also express gratitude to Mr. Franklin A. Ayer of the Research Triangle Institute, and his staff members Loren Clarke, Roger McGuffey, Branda Idol, Helen Centwell, Dianna Morgan, and Denise McCampbell for the smooth manner in which the conference proceeded, and the efficient operation of the conference facilities and support services.

John L. Buckley
General Chairman

NPC00026590

753927

Table of Contents

(* indicates speaker)

	Page
19 November 1975	
Opening Remarks	1
John L. Buckley, Ph.D., General Chairman	
Keynote Address: Environmental Protection Rx for Public Health	5
The Honorable Russell E. Train	
Session I: HEALTH EFFECTS AND HUMAN EXPOSURE	11
David P. Rell, M.D., Ph.D., Session Chairman	
Introductory Remarks	13
David P. Rell, M.D., Ph.D.	
Some of the Recent Findings Concerning Yusho	14
Masanori Kuratsune, M.D.,*	
Yoshito Matuda, and	
Junya Nagayama	
Pathological Findings Associated With Chronic Experimental Exposure to PCB's	30
Renate Kimbrough, M.D.	
Summary of Toxicological Studies on Commercial PCB's	35
J. C. Calandra, M.D., Ph.D.	
Pathobiological Responses of Primates to Polychlorinated Biphenyl Exposure	43
James R. Allen, D.V.M., Ph.D.,* and	
D. H. Norback	
PCB Chlorination Versus PCB Distribution and Excretion	50
H. B. Matthews, Ph.D.,* and	
M. Anderson, Ph.D.	
Enzymatic and Other Biochemical Responses to Selected PCB's	57
D. J. Ecobichon, Ph.D.	
Toxicology of Selected Symmetrical Hexachlorobiphenyl Isomers: I. Biological Responses in Chicks and Mice	67
Marco Biocci, M.D.,*	
J. A. Moore, D.V.M.,	
B. N. Gupta, B.V.Sc., Ph.D., and	
J. D. McKinney, Ph.D.	
Toxicology of Selected Symmetrical Hexachlorobiphenyl Isomers: Correlating Biological Effects with Chemical Structure	73
James D. McKinney, Ph.D.	

Table of Contents (con.)

	Page
Toxicity of 2,3,7,8-Tetrachlorodibenzofuran—Preliminary Results	77
John A. Moore, D.V.M.,	
B. N. Gupta, B.V.Sc., Ph.D., and	
J. G. Vos, D.V.M., Ph.D.	
Session II: USES, SOURCES, AND IDENTIFICATION	81
David Garrett, Session Chairman	
Introductory Remarks	83
David Garrett	
Characterization of Polychlorinated Biphenyls	84
James P. Mieure, Ph.D.,*	
O. Hicks,	
R. G. Kaley, Ph.D., and	
V. W. Saeger, Ph.D.	
Overview of Analytical Identification and Spectroscopic Properties	94
Stephen Safe, Ph.D.	
Production and Usage of PCB's in the United States	103
Robert L. Durfee, Ph.D.	
PCB Disposal, Reclaiming, and Treatment	108
Thomas E. Kopp	
Sources of Polychlorinated Biphenyls in Wisconsin	124
Stanton Kleinert	
Polychlorinated Biphenyl Usage and Sources of Loss	
to the Environment in Michigan	127
John L. Hesse	
General Discussion of Session II	134
20 November 1978	
Session III: ENVIRONMENTAL FATE AND OCCURRENCE	135
Ian C. T. Nisbet, Ph.D., Session Chairman	
Introductory Remarks	137
Ian C. T. Nisbet, Ph.D.	
Residues of Polychlorinated Biphenyls in the General Population	
of the United States	139
Frederick W. Kutz, Ph.D.,* and	
S. C. Strassman	

Table of Contents (con.)

	Page
PCB Residues in Human Adipose Tissue and Milk	144
Donald Grant, Ph.D., [*] J. Mes, and R. Frank	
Levels of PCB's in the U.S. Food Supply	147
Charles Jelinek, Ph.D., [*] and P. E. Corneliusen	
Levels of PCB's in Canadian Commercial Fish Species	155
John M. Graham	
The Occurrence of PCB in the National Fish and Wildlife Monitoring Program	181
Charles R. Walker	
Trends of Polychlorinated Biphenyls in Three Lake Michigan Fishes	177
Wayne A. Willford, Ph.D., [*] Robert J. Hesselburg, and Lawrence W. Nicholson	
A Note on Polychlorinated Biphenyls in Air	182
Frederick W. Kurtz, Ph.D., [*] and Henry S. C. Yang	
Polychlorinated Biphenyls in the Surface Waters and Bottom Sediments of the Major Drainage Basins of the United States	183
D. Steve Dennis, Ph.D.	
PCB's in Agricultural and Urban Soil	195
A. E. Carey and J. A. Gowen (Presented by D. Steve Dennis)	
Marine Inputs of Polychlorinated Biphenyls off Southern California	199
David R. Young, Deirdre J. McDermott, [*] and Theodore C. Heesen	
PCB Contamination of Southern California Marine Organisms	209
Deirdre J. McDermott, [*] David R. Young, and Theodore C. Heesen	
Transport of Chlorinated Hydrocarbons in the Upper Chesapeake Bay	218
T. O. Munson, Ph.D., [*] H. D. Palmer, Ph.D., and J. M. Forns	

Table of Contents (con.)

	Page
Recent Studies of Transport of PCB's to Marine Environments	230
Robert W. Risebrough, Ph.D.	
Uptake of Three Polychlorinated Biphenyls, DDT and DDE by the Green Sunfish, <i>Lepomis Cyanellus</i> Raf	238
James R. Sanborn, William F. Childers, and Robert L. Metcalf	
(Paper previously published but not presented at conference.)	
Laboratory Model Ecosystem Studies of the Degradation and Fate of Radiolabeled Tri-, Tetra-, and Pentachlorobiphenyl Compared with DDE	243
Robert Metcalf, James R. Sanborn, Ph.D., Po-Young Lu, and Donald Nye	
(Paper previously published but not presented at conference.)	
Environmental Transport and Occurrence of PCB's in 1975	254
Ian C. T. Nisbet, Ph.D.	
General Discussion of Session III	257
Session IV: ECOLOGICAL EFFECTS AND EXPOSURE	259
Donald I. Mount, Ph.D., Session Chairman	
Introductory Remarks	261
Donald I. Mount, Ph.D.	
Summary of Recent Information Regarding Effects on PCB's on Birds and Mammals	262
Ray C. Stendell, Ph.D.	
Pre-1972 Knowledge of Nonhuman Effects of Polychlorinated Biphenyls	268
Charles R. Walker	
PCB's: Effects on and Accumulation by Estuarine Organisms	282
David J. Hansen	
Summary of Recent Information Regarding Effects of PCB's on Freshwater Organisms	284
Alan V. Nebeker, Ph.D.	

NPC00026594

Table of Contents (con.)

	Page
Distribution and Excretion of [¹⁴ C]-2,4,5,2'5'-Pentachlorobiphenyl in the Lobster (<i>Homarus americanus</i>) and the Dogfish Shark (<i>Squalus acanthias</i>) John R. Bend, Ph.D., Larry G. Hart, Ph.D., Anthony M. Guarino, Ph.D., David P. Rall, Ph.D., and James R. Fouts, Ph.D.	292
Session V: ECONOMICS AND SUBSTITUTES Warren Muir, Ph.D., Session Chairman	303
Introductory Remarks Warren Muir, Ph.D.	305
PCB's in Capacitor Applications Richard Rollins	306
The Economic Impact of a Ban on Polychlorinated Biphenyls Duncan MacArthur* and Stephen F. Nagy	309
The Use of Dow Corning® Q2-1090 Dielectric Liquid in Power Transformers Richard H. Montgomery	312
Dow XFS-4169L: An Environmentally Acceptable Capacitor Fluid Dean Branson, Ph.D.	314
Chlorinated Biphenyl Dielectrics—Their Utility and Potential Substitutes David Wood	317
Some Comments on Alternatives to PCB's Bruno Ray Coquais	325
PCB's and Their Substitutes — A Brief Look at Some Examples of Past Tradeoffs Dale Hattis, Ph.D.,* and Albert Murray, Ph.D.	332
ENJ-2065—An Electrical Insulating Fluid E. J. Inchalik, Ph.D.	334
General Discussion of Session V	338

Table of Contents (con.)

	Page
Session VI: GENERAL SESSION	341
Introduction	
John L. Buckley, Ph.D., General Chairman	343
Christopher M. Timm, Session Chairman	343
Statements on Behalf of Commercial Fishing Interests, Green Bay, Wisconsin	
Jean Hermes	343
Glorianne Hermes	343
Gene Lambrich	344
Statement on Behalf of National Fisheries Institute, Washington, D.C.	344
Lee Weddig	
PCB Body Burdens Deny Full Use of the Great Lakes Fishery Resource	345
Carlos M. Fetterolf, Jr.	
Primate Study	347
Wilbur P. McNulty, M.D.	
Ultrastructural Features of Gastric Mucosa and Sebaceous Glands After	
Ingestion of Aroclor 1242 by Rhesus Monkeys	350
Mary Bell, Ph.D.	
The View of the Paper Industry on the Occurrence on PCB's	
in the Environment and the Need for Regulation	359
Paul E. Trout	
Statement on Behalf of Westinghouse Electric Corporation,	
Pittsburgh, Pennsylvania	361
Bernard A. Kerns	
Statement Relating to Polychlorinated Biphenyls on Behalf of	
the Wisconsin Paper Council	362
James S. Haney	
Statement on Behalf of United Electrical Workers Union,	
New York, New York	364
David Kotalchuck	
Better Late Than Never: The Case for Treating PCB's	
As Toxic Substances Now	365
Lee Botts	
A Failure of Government	367
Richard R. Knabel	

Table of Contents (con.)

	Page
Statement of a Concerned Citizen	369
Eileen Johnston	
Letter to Mr. Russel B. Train, Administrator, U.S. Environmental Protection Agency	371
Ray Oltmanns	
A Call for Local Government Action	372
State Senator Burnett Bauer	
Statement on Behalf of Minnesota Pollution Control Agency, Roseville, Minnesota	373
Berry Schade	
Statement on Behalf of Bio-International, Inc., Woods Hole, Massachusetts	376
Richard T. Ferry	
The Duwamish Spill	
Major Gordon Goff	377
John S. Thompson	378
Chlorination of Waters for Disinfection - A Study of the Production of Undesirable Chlorinated Products	379
Richard E. Johnson, Ph.D.	
Statement on Behalf of Tivian Laboratories, Providence, Rhode Island	384
Herbert Gilner	
The Need for Cost-Benefit Analysis in Toxic Substance Usage	384
A. Estock	
Comments and Conclusion	
Christopher M. Timm	400
Carlos Fetterolf, Jr.	400
John Chastam	401
John L. Buckley, Ph.D.	401
COMMUNICATIONS TO THE CONFERENCE	403
Some Additional Comments With Respect to Ambient Air Sampling for PCB's	405
Gordon H. Thomas	
"Dow Imbibitor Bead"	406
Jack Taylor	

Table of Contents (con.)

	Page
Citizen Involvement Awareness of Communication	405
Dorcas Thompson	
Letter to Conference on Polychlorinated Biphenyls	406
Susan E. Caswell	
Letter to the Administrator of the Environmental Protection Agency	407
Mrs. Meredith C. Tucker	
Letter to Lake Michigan Federation	408
Chairperson, Pesticide Committee, Knob & Valley Audubon Society of Southern Indiana	
Letter to the Environmental Protection Agency, Region V	408
Douglas V. Whitesides, Jr.	
21 November 1975	
Session VII: APPROACHES TO CONTROL	409
John L. Buckley, Ph.D., Session Chairman	
Introductory Remarks	411
John L. Buckley, Ph.D.	
A Review of Federal and State Government Roles in Controlling Impacts of PCB's on the Environment	412
A. Karim Ahmed, Ph.D.	
FDA Regulation of PCB's in Food	428
John R. Wessel	
Programs and Authorities of the Environmental Protection Agency	431
Walter C. Barber	
U.S. Federal Agency Roles and Actions: The Department of the Interior	434
The Honorable Nathaniel P. Reed	
U.S. Federal Agency Roles and Actions: National Institute of Occupational Safety and Health	438
Richard A. Rhoden, Ph.D.	
Proposed Canadian Regulatory Measures for PCB's	440
Morris F. Millson, Ph.D.	
PCB's in Foods: A Look at Federal Government Responsibilities	443
Joseph Highland, Ph.D.	

Table of Contents (con.)

	Page
Concerns and Recommendations of the National Marine Fisheries Service Regarding Approaches to Control the Polychlorinated Biphenyls Problem	451
Thomas J. Billy	
The Role of the Coast Guard in PCB Pollution Control	453
Lt. Cmdr. J. A. MacDonald	
Considerations by the Department of Transportation	454
Alfred W. Gralls	
Observations on and Summary of Session VII	455
Alfred Kolbye, M.D., M.P.H., J.D.	
Session VIII: SUMMARY SESSION	457
John L. Buckley, Ph.D., Discussion Chairman	
Summary of Session I	459
J. G. Vos, D.V.M., Ph.D.	
Summary of Session II	461
David Garrett	
Summary of Session III	461
Ian C. T. Nisbet, Ph.D.	
Summary of Session IV	462
Donald I. Mount, Ph.D.	
Summary of Session V	463
Nicholas A. Ashford, Ph.D.	
Summary of Session VI	465
Christopher M. Timm	
Summary of Session VII	466
Charles N. Gregg, Jr.	
Conference Highlights	468
Richard A. Carpenter	

19 November 1975

OPENING REMARKS

John L. Buckley, Ph.D.*
General Chairman

*Consultant, Office of Research and Development, Environmental Protection Agency, Washington, D.C.

NPC00026600

753937

OPENING REMARKS

John L. Buckley, Ph.D.*

I'd like to call this meeting to order. I am John Buckley, with the Environmental Protection Agency. I'd like to welcome you here to this National Conference on PCB's, with the subtitle of PCB's in the Environment in 1975.

Most of you in the room are from the United States, but there has been major participation from our Canadian neighbors to the north, and in addition, to my knowledge, representatives from France, Belgium, the Netherlands, and Japan.

I'd like to extend my personal thanks to my many colleagues in the EPA both in Washington and in the regions and in the laboratories, and my colleagues in other Federal agencies, in the industry, and in academia who were helpful in getting this conference organized in the very short period of time we had. I think almost everyone that I talked to and invited and asked to partic-

*Consultant, Office of Research and Development, Environmental Protection Agency, Washington, D.C.

ipate has agreed to do so, and I really look forward to the next 2 days as a great opportunity.

As I have gone through the process of helping to arrange the program, many questions have come to mind. Most of these are listed in the program, and I guess my aspiration is that we have some additional insights, perhaps some answers in relation to those questions before we leave.

I think there is a great opportunity for us to learn together and to go forward from here with a better common understanding and perception of the situation in regard to PCB's in the environment.

I'd ask you to remember that we're here to try and assemble and evaluate what we jointly know, and we're here also to avoid conclusions as to what it all means. It doesn't mean we need not reach conclusions, but it does mean it's probably not appropriate to try and tie everything down and understand just where we've been by the end of this meeting.

19 November 1975

KEYNOTE ADDRESS

The Honorable Russell E. Train*

***Administrator, Environmental Protection Agency, Washington, D.C.**

ENVIRONMENTAL PROTECTION RX FOR PUBLIC HEALTH

Russell E. Train*

More than 4 years ago, while I was serving as Chairman of the President's Council on Environmental Quality, a Federal interagency task force began addressing itself to the same basic question that concerns this conference: What do we know and what should we do about polychlorinated biphenyls, or PCB's?

In its report of May 1972, the task force concluded that PCB's were highly persistent, could be found in all parts of the environment, could "bioaccumulate" to relatively high levels in fish, and could have serious adverse effects on human health. The task force recognized, at the same time, that for uses in closed electrical systems, PCB's had some very real advantages over other materials. They conduct heat, but not electricity. The only available substitutes for use in capacitors and in transformers—which are widely used in indoor electrical systems—were flammable. It appeared that to ban PCB's from these uses would be, in effect, to substitute a safety hazard for a health hazard.

The task force, as a result, recommended the discontinuance of all current uses of PCB's except in closed electrical systems. It also called for early enactment of the Toxic Substances Control Act to provide the regulatory authority required not only to deal more effectively with the problems posed by PCB's and other chemicals already in the environment, but to take sensible steps to prevent such chemicals from posing such problems in the first place.

Already in 1972, the sole American producer of PCB's had voluntarily restricted the sales of PCB's to uses in closed electrical systems. Both the Food and Drug Administration and the Environmental Protection Agency announced actions designed to reduce the levels of PCB's in our food and our waters.

The United States asked the Organization for Economic Cooperation and Development (OECD) to take appropriate action, on the international level, to control PCB's. In February 1973, in the first international agreement aimed at limiting the production and use of chemicals in order to protect the environment, the member countries of the OECD announced their decision to prohibit the use of PCB's for industrial or commercial purposes except in certain closed systems. I might add that one member country, Japan, after PCB contamina-

tion of rice oil adversely affected 1,000 people, has banned the future production or import of PCB's.

We believed that all these measures added up to an effective, comprehensive program that would "take care" of the PCB problem, and would enable us to continue to take commercial advantage of the unique properties of PCB's while insulating the public and the environment against exposure to hazardous levels of these chemicals.

Instead, more than 3 years later, we find that, although PCB levels in food have steadily declined, PCB's are present in our environment to a far greater degree and at higher levels than we have previously thought. We have found high PCB levels—levels greatly exceeding FDA guidelines—in salmon, striped bass, and other fish in the Great Lakes, the upper Mississippi River, Southern California, the Gulf of Mexico and in the Hudson River and other waterways in New York State. Our selective sampling of drinking water disclosed the presence of PCB's in the water supply of two communities.

The evidence we have accumulated over the past 3 years has underscored our original concern over the toxicity of PCB's and over the potential health hazard posed by the presence of high PCB concentrations in waterways, in water supplies, and in fish. This, in brief, is the situation we find ourselves in today.

We have called this conference to help us deal with it, to determine, as I said at the outset, what we know and what we should do about PCB's.

We do know one thing that we *must* do, that we should have done 3 years ago when the task force urged us to do so, and that, had we done it, might have enabled us to really come to grips with the PCB problem and rendered this conference unnecessary—that is, to enact an effective toxic substances control law. I cannot help but recall that when I became the first Chairman of the Council on Environmental Quality in February 1970, my very first directive to our small staff was to develop a legislative proposal for dealing with this class of problem. The time had clearly come for an effective mechanism to deal broadly with such problems, not only after the fact, but also to help prevent their occurrence in the first place.

Almost 5 years have now passed since President Nixon first proposed such legislation to Congress. Over those 5 years we have introduced into the commercial market an estimated 600 chemical compounds annually. We have done so without any systematic, advance assess-

*Administrator, Environmental Protection Agency, Washington, D.C.

ment of their potential impact upon public health. Yet, as we have learned through our experience with such materials as vinyl chloride, we may not discover how harmful a compound can be until years after it has become a rather commonplace item in our everyday lives, even a significant factor in our economy. Also, again and again we find ourselves engaged in an extremely difficult and drawn-out struggle to protect the public from a hazard to which it has already been exposed while at the same time trying to avoid putting people out of business or out of work. We find ourselves trying to choose between a health hazard and a safety hazard. We find ourselves without the authority we need to really cope with the problems posed by PCB's, the authority to limit selected uses and distribution of PCB's as well as to require testing concerning the health and ecological effects of proposed substitutes.

With regard to PCB's, we will continue to address the problem as effectively as we can under existing authorities, especially under the Water Act, while at the same time recognizing the inherent inadequacies of the piecemeal approach we are forced to take. We are also working on measures we would propose under any toxic substances bill that may be enacted. They would take into account, not only the available information on toxicity and exposure levels, but also the impact of any regulatory steps upon business, employment, and the economy. I look forward to the contributions this conference can make to the development of an effective regulatory program for PCB's both under existing authority and under a toxic substances law.

About a month ago, in testimony prepared for delivery before the Environment Subcommittee of the Senate Commerce Committee, Dr. David Rall, who is scheduled to follow me this morning, said, and I quote, "Toxic substances control legislation which prevents the exposure of segments of the population to disease-producing substances is a key element of preventive medicine." There is, indeed, an increasing body of evidence, and an impressive array of expert opinion that we may be approaching the whole question of human health from the wrong side, that, as a matter of national policy as well as of personal practice, an ounce of prevention may well be worth a pound of cure.

The Department of HEW estimates that our total national health bill this year will add up to nearly \$120 billion. Yet a good many informed observers believe that, because most of that money goes for cure rather than prevention, we are not getting what we pay for. Our traditional health care system, they say, simply cannot cope with environmentally-induced diseases. Dr. Ernst L. Wynder, president of the American Health Foundation, has pointed out that heart disease, cancer,

stroke, and accidents account for 70 percent of deaths among Americans. And the chief causes of these diseases are "environmental" in the broadest sense of that term. "Thus," Dr. Wynder concludes, "in a society where infectious diseases have been largely overcome through sanitary measures, immunization, and antibiotics, the major causes for today's death toll are chronic diseases. This death toll is largely due to unhealthy life styles, unhealthy working environments and disease-producing products."

The more sophisticated and sensitive our monitoring devices become, and the more data we accumulate on the health effects of pollutants and other agents in the environment, the worse things look. Over a year ago, scientists uncovered disturbing evidence that children, whom we had believed unaffected in any lasting way, can contract chronic and acute disabilities as a result of air pollution. As many as 20 percent of the children in a city such as New York, one study concluded, can develop severe and chronic respiratory diseases. Another study in a southern city with relatively heavy air pollution had similar results. More recently, a group of scientists reported that the most significant factor in a dramatic drop in deaths in the San Francisco area during the gas shortage early last year—a 13.4 percent decrease in deaths compared with the same period over the previous 4 years—was reduced exposure to pollutants from auto exhausts.

We are spending around \$1 billion this year on research into cures and causes of cancer. The National Cancer Institute has estimated that the actual cost of cancer to people amounts to tens of billions of dollars a year. Yet the World Health Organization estimates that from 60 to 80 percent of all cancer is the result of "environmental" factors, again, in the broadest sense of that term. We have all read the news stories recently concerning the 1975 Nobel award to three American scientists for research into possible links between viruses and cancer. I was struck by the fact that, in their first public statements upon receiving the award, two of these scientists stressed the fact that, in the words of one of them, Dr. David Baltimore of the Massachusetts Institute of Technology, "the role of viruses in cancer is small" and that "the best hope today for cures is research into environmental causes of cancer." "This," Dr. Baltimore went on to say, "is a good place to put funds now."

We should understand, as well, that while environmental protection often appears to involve substantial costs, we really have no choice about whether or not we are going to bear these costs. Society has already been bearing these costs in one form or another—in the loss of recreational uses of rivers and beaches; in the increased treatment costs of our drinking water; in the damage

from air pollution to buildings, farm crops, and forests; and most importantly, through medical and hospital bills, time lost on the job because of illness, human suffering, earlier mortality, and the like. When we control and cut pollution at the source, we are shifting its costs from the shoulders of society as a whole onto those of the polluter, where they belong in the first place. Such costs then tend to be passed on to the polluter's customers. But this is the most efficient way of allocating these costs and of encouraging, at the same time, the development of both processes and practices that generate less pollution. Moreover, all our experience indicates that the cost of the particular pollution to society as a whole is usually far greater than the cost of cleanup and control. We estimate, for example, that measurable annual damages of \$11.2 billion from particulates and sulfur oxide are more than twice the annual costs of control.

What all of this suggests to a layman such as myself is that both our popular understanding of, and our public approach to, health care and disease control are going to have to undergo a searching reexamination and, I suspect, radical revision. It suggests that, some of our most effective "health care" dollars, at least when they are well spent, may be the "disease prevention" dollars we spend to curb and control pollution and other agents that we introduce into our own environment. It suggests

that the battle against disease must increasingly be fought, not simply in the hospitals and the doctors' offices, but in our streets and our homes and our offices, in our air and our water, in our food and our products, in our personal habits and lifestyles. It suggests that if, in the words of Dr. Irving Selikoff of the Mount Sinai School of Medicine in New York, "environmental disease is becoming the disease of the century," then environmental protection, in the broadest sense of the phrase, must become the most important ingredient in any national health program.

Such a broad prescription may seem far removed from the more immediate and urgent concerns of this conference. But I think we all understand that it is our failure to get at the real roots of the problem that concerns us here, and our preoccupation instead with the symptoms and surfaces and single instances of things that has made this conference and the problem it addresses so critical.

At the start of my remarks, I successfully resisted the temptation to issue the dramatic announcement that this was my last PCB's conference. It is, however, my fervent hope that you do your work so well at this conference that we will never need to call another one. I thank you for coming, and I look forward to seeing the results of your work.

19 November 1975

Session I:

**HEALTH EFFECTS AND
HUMAN EXPOSURE**

David P. Rall, M.D., Ph.D.*
Session Chairman

*Chairman, Department of Health, Education, and Welfare Committee to Coordinate Toxicology and Related Programs, and Director, National Institute of Environmental Health Sciences, National Institute of Health, Research Triangle Park, North Carolina.

INTRODUCTORY REMARKS

David P. Rall, M.D., Ph.D.*

The history of PCB's is a remarkable case study in the continuing story of toxic substances and the public health. From 1929, when it was first manufactured in the United States, until 1986, it was presumed that this substance was being used primarily in a closed environment. However, in 1966 PCB's were found in fish in the Baltic Sea. Then they were discovered in birds and other animals. Since then it has been demonstrated they have an almost global distribution. Three years after being discovered as an environmental contaminant, they were determined to be the causative agent in an outbreak of a disease in Japan now called "Yusho" or "oil" disease.

Thus, in a relatively short period of time, we saw a manmade compound introduced into commerce for a relatively narrow purpose, a closed use, broadened through new applications, and discovered to be hazardous to animals, birds, fish, and to man. In slightly more than two generations, we had closed the all-too-frequent circle of progress: product development, distribution, use, and resulting hazard to human health.

In 1971, we became concerned that the PCB's appeared to be an ever-expanding problem whose potential limits were essentially unknown. Thus, in December of 1971 we called a 2-day open meeting to discuss the entire range of current and potential health problems associated with the widespread use and dispersion of PCB's. The meeting was broadly attended by scientists and administrators throughout the world who were concerned with this problem.

The scientists at that meeting focused on the entire spectrum of problems that needed investigation. Their papers ranged from biological concerns: animal toxicology, mechanisms of action, and human body burden; to regulatory and control concerns: environmental transport, distribution, and alteration, and occurrence. In his

"Where do we go from here" summary, Dr. Norton Nelson singled out two general areas of concern.(ref.1).

First, relative to environmental distribution patterns, including: (1) further refinement of sources, and (2) better quantitation of discharge amounts by route into water and air. Second, he pointed out that there were inadequate data to determine if the PCB's caused malignant tumors in laboratory animal studies and urged that we follow the ongoing studies with care. He also pointed out the potential deleterious effects of the PCB's on reproduction in mammals.

In following up these and the other points Dr. Nelson made, scientists, many of them in DHEW, have been engaged in attempting to develop the information required for the resolution of the biological aspects of this problem. Last month, in order to insure that our Department's efforts are as effective as possible, we established a Subcommittee on PCB's of the DHEW Committee to Coordinate Toxicology and Related Programs.

Through this Subcommittee we will:

1. Assemble, review, and interpret data that assess the health significance of polychlorinated biphenyls, and
2. Formulate recommendations as to future research needs.

In all of these efforts, we will be cooperating with those agencies which must carry out regulatory responsibilities in this difficult area. Continuing collaborative efforts by biological scientists here and abroad have brought us far toward the resolution of these problems. The reports which you will hear relating to Health Effects and Human Exposure in the session which follows should indicate the progress which we have made since the 1971 conference.

REFERENCE

1. Norton Nelson, "Comments on Research Needs," *Environmental Health Perspectives* 1 Vol. 1 (April 1972), pp. 181-185.

*Chairman, Department of Health, Education, and Welfare Committee to Coordinate Toxicology and Related Programs, and Director, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina.

SOME OF THE RECENT FINDINGS CONCERNING YUSHO

→ Masanori Kuratsune, M.D.,*
Yoshito Masuda,** and Junya Nagayama*

Abstract

Analysis of Yusho disease, which was first detected in 1968, has been limited and analyses have produced varying results. Yusho oil has been determined to contain a high level of polychlorinated dibenzofurans (PCDF's). Nagayama et al. found that PCDF levels in the oil were especially high when the oil was contaminated with PCB's used as a heat transfer medium. Their studies also showed that the concentration of PCDF's is much closer to that of PCB's in liver than in adipose tissues in patients with Yusho.

The current clinical state of patients with Yusho is discussed at length. Subjective symptoms, dermatological findings, serum triglyceride levels, liver conditions, mortality rates, and the effects on children born to mothers with Yusho are all reported.

INTRODUCTION

More than 7 years have passed since the outbreak of an epidemic of Yusho in 1968. According to the latest tabulation, Prof. Omae, current chief of the Study Group for the Therapy of Yusho, reported that a total number of 1,291 patients have been registered as Yusho in 22 prefectures of Western Japan by April 30, 1975 (ref. 1).

We would like to describe some of the recent findings concerning Yusho which we think to be particularly relevant for understanding of toxicity of PCB's. For more detailed information, readers are advised to refer to original papers appearing mainly in the fourth and fifth reports of the study on Yusho and PCB (ref. 3). Most of the patients described in these reports are those living in Fukuoka prefecture. Published information of patients living in other areas are unfortunately very few, so with a few exceptions no reference will be made to them.

*Masanori Kuratsune and Junya Nagayama are with the Department of Public Health, Faculty of Medicine, Kyushu University, Division of Analytical Chemistry, Daiichi College of Pharmaceutical Science, Fukuoka, Japan.

**Yoshito Masuda is with Daiichi College of Pharmaceutical Sciences, Fukuoka, Japan.

PCB's IN THE BODIES OF PATIENTS WITH YUSHO

1. Tissues

First of all, the concentration of PCB's retained in the tissues and fluids of patients with Yusho should be referred to before their current clinical state will be discussed.

Although no accurate estimation is feasible because of the very limited number of analyses so far made, the concentration of PCB's in adipose tissues of patients seems to have been fairly high soon after the occurrence of poisoning—that is, in November 1968, at least 1 month after the discontinued use of the toxic rice oil by patients, as shown in table 1. The corresponding concentrations were considerably lower in 3 patients who died in the next year, 1969. However, no such marked difference could be seen between those who died in 1969 and the subsequent decedents, although cases 7 and 10, who died in 1970 or 1975, showed quite low levels of PCB's in adipose tissues. As compared with the figures available from a nationwide survey on residual PCB's in autopsied tissues, the levels noted in the recent decedents are considered to be fairly close to the usual level of ordinary autopsied materials. Similar facts were also noted for PCB concentration in the skin and liver.

2. Blood

Since the analysis of PCB's in blood started only after 1972, no figures are available in regard to the blood levels of PCB's in patients in the earlier stage of poisoning. As shown in table 2, however, it is clear that the blood levels of patients had approached the level of ordinary persons already in 1972, although they were still significantly higher than that level. This fact as well as the previous fact of lowered tissue levels of PCB's in recent decedents seem to be rather surprising if we consider also that the majority of patients are still showing various clinical symptoms, as will be discussed later.

3. Gaschromatographic Patterns of PCB's in the Bodies of Patients

Masuda first noted a peculiar common gas-chromatographic pattern of PCB fractions isolated from various tissues, blood, and breast milk of patients with Yusho and called the attention of the Study Group for the Therapy of Yusho to it in early 1972. Figure 1 shows a typical example of such a pattern in comparison

Table 1. PCB's concentration in tissues of patients with Yusho and other diseases

Case	Time of death, operation	PCB's (ppm)						Ref- erence
		Skin		Adipose tissue		Liver		
		Whole basis	Fat basis	Whole basis	Fat basis	Whole basis	Fat basis	
Case 1 High school boy	Nov. 1968			76 (face) 13 (abdomen)				
Case 2, 3 Adult male, female	Nov. 1968			32, 46 (cheese-like substance from acneform erup- tions)				10
Case 4 Boy, 13 yr	July 1969			1.3 (mesentery)	3.7	0.14	9.5	
Case 5 Male, 25 yr	July 1969	1.2	8.7	2.8 (mesentery)	15.1	0.2	10.4	
Case 6 Male, 73 yr	Nov. 1969	1.0	4.4	3.8 (mesentery)	8.4	0.07	3.1	11, 12
Case 7 Female, 48 yr	Dec. 1970	0.6	0.8	0.7 (mesentery)	0.9	0.07	1.3	
Case 8 Male, 46 yr	May 1972	1.8	3.2	4.3	6.5	0.08	8.4	
Case 9 Female, 33 yr	Sept. 1972			1.9 (subcutaneous)	2.9			
Case 10 Male, 72 yr	April 1975			0.19 (mesentery)	0.4	0.04	3.0	14
National survey Males and females 25 - 49 yr	1973	0.04 - 1.7 (n = 54)		0.2 - 4 (n = 47)	0.3 - 6.4 (n = 48)	0.01 - 0.6 (n = 51)	0.02 - 3.1 (n = 30)	13

Table 2. PCB's in blood patients with Yusho, workers and ordinary persons

Material	No. of subjects	Time of examination	PCB's (ppb) Whole basis mean $\pm$ S.D.	Range	Reference
<u>Whole blood</u>					
Yusho patients	41	March - August 1973	7	2-26	7
Ordinary persons	37	1972	3	1-7	
<u>Plasma</u>					
Yusho patients	15	Jan. 1972	6.3 $\pm$ 4.0	2-15	8
Normal persons	82		3.0 $\pm$ 1.3	1- 7	
<u>Whole blood</u>					
Yusho patients	25	Jan. 1972	4.8 $\pm$ 2.9	1-12	8
Normal persons	11		2.8 $\pm$ 1.5	1- 6	
<u>Whole blood</u>					
Workers ^a	23	1972	364 $\pm$ 262	60-920	9

^aWorkers engaged in the production of Kanechlor 200-600 in the air containing 0.05 to 0.2 mg/m³ of PCB's [Kanechlor-300 + Kanechlor-400 (1:1)]. Two of them showed dermal signs.

with the common one seen in ordinary persons, which is very much close to that of a mixture of Kanechlor 500 + 600 (1:1). It is easily notable that the peak 1, which appears immediately after p,p'-DDE in the gas chromatogram in figure 1, is very low in patients with Yusho as compared with ordinary persons, while the peak 5 is much more prominent in Yusho than in ordinary persons. Masuda and his associates observed this peculiar pattern (designated as type "A") in blood of about 60 percent of patients with Yusho, and a somewhat similar pattern (designated as type "B") in about 37 percent (refs. 4,7,11,12).

Takamatsu et al. also observed the same peculiarity in the blood of patients with Yusho (ref. 8). It was further demonstrated that those patients who show the peculiar gas-chromatographic pattern as designated as pattern A by Masuda et al. have a higher average concen-

tration of PCB's in their blood than do other patients (refs. 4,7). Abe et al. (ref. 23) examined in 1974 the PCB residues in the plasma of 30 children born to 18 mothers who had consumed Yusho oil at Goto Islands, Nagasaki prefecture. The specific gas-chromatographic pattern of type A was seen among 24 percent of the children and 44 percent of their mothers, but the peculiarity seemed somewhat less marked as compared with the one seen among patients in Fukuoka prefecture.

The chemical and toxicological nature of the compound or compounds yielding the above-mentioned peak 5 must be clarified but have not yet fully been examined. Masuda, however, considers the peak 5 to be 3,4,2',3',4',5'-hexachlorobiphenyl, judging from its retention time on the Apiezon L column developed by Jensen and Sundström (ref. 22).

A : FATTY TISSUE OF YUSHO PATIENT
 B : FATTY TISSUE OF ORDINARY PERSON
 C : KANECHLOR 500 + 600 (1:1)




Figure 1. Gaschromatograms (ECD) of PCB's on SE-30.

POLYCHLORINATED DIBENZOFURANS IN KANECHLORS, "YUSHO OIL," AND TISSUES OF PATIENTS

1. Polychlorinated Dibenzofurans in Kanechlors and "Yusho oil"

Recently Nagayama et al. analyzed Kanechlors and three samples of toxic "Yusho oil" used by three independent families with Yusho for polychlorinated dibenzofurans (PCDF's) and polychlorinated dibenzo-p-dioxins (PCDD's) (ref. 16). They did a column chromatographic fractionation of PCDF's and PCDD's from a bulk of PCB's by using activated alumina as adsorbent, and n-hexane, n-hexane containing 20 percent carbon tetrachloride, or n-hexane containing 20 percent methyl-enchloride as eluent. The fractions thus obtained were subjected to gas-chromatographic and mass-spectrometric examination. Quantitative estimation of PCDF's and PCDD's was made by two methods, namely by measuring the gas chromatographic peak heights and by measuring the gas chromatographic peak area of per-chlorinated derivatives of these compounds.

Although no PCDD's were found in any of these samples, PCDF's were found in all of them. As shown in table 3, KC-400 contained the highest concentration of

PCDF's, about 18 ppm of PCDF's consisting of dichloro- up to pentachloro- dibenzofurans. A peak with the same retention time as that of 2,3,7,8-tetrachlorodibenzofurans, which was kindly provided by Dr. J. G. Vos, was noted in its gas chromatogram. All of the three samples of "Yusho oil" also contained about 5 ppm of PCDF's, the major constituents of which were tetra- and pentachlorodibenzofurans. Here again, the peak with the same retention time as 2,3,7,8-tetrachlorodibenzofuran was noted. Kashimoto also found 1.6 ppm of PCDF's in another batch of "Yusho oil," as shown in table 5 (ref. 18). Table 4 summarized the concentrations of PCDF's in Kanechlor-400, reported by several authors. As clearly noted, there is a fairly large discrepancy in their findings. Whether or not it was due to their analytical procedures or to batch difference cannot be decided at the present time.

Another important fact was disclosed by Nagayama et al. They determined the concentration of PCB's in "Yusho oil" as approximately 1,000 ppm or slightly less than 1,000 ppm, as shown in table 3. Since "Yusho oil" is known to have been contaminated with Kanechlor-400, the ratio of the concentration of PCB's to that of PCDF's in "Yusho oil" is expected to be about 1,000:0.018. The observed ratio, approximately 1,000:5,

Table 3. PCDF's and PCB's in Kanechors and Yusho oil

Sample		PCDF's (ppm)		PCB's (ppm)	
		Peak height method	Perchlorination method	Peak height method	Perchlorination method
Kanechlor	300	1	1.5	-	-
	400	18	16.6	-	-
	500	4	2.5	-	-
	600	5	2.7	-	-
Yusho oil	A	5	4.4	830	870
	B	4	5.1	900	920
	C	5	5.2	1030	980

Table 4. Reported concentrations of PCDF's in Kanechlor-400

Authors	Year	Concentration (PPM)
Roach et al. ^a	1974	1
Nagayama et al. ^b	1975	18
Kashimoto et al. ^c	1975	33

^aRef. 17.^bRef. 16.^cRef. 18.

was thus about 250 times higher than expected (table 5). The reasons for this great discrepancy are not clear yet. It should be noted, however, that the sample of Kanechlor-400 analyzed was an "unused" one, while the Kanechlor-400 present in "Yusho oil" was "used" as heat transfer medium. This fact suggests a practically important possibility that Kanechlor-400 and probably other commercial PCB's, too, will increase their PCDF concentrations when used as heat transfer medium.

2. PCDF's in Tissues of Patients with Yusho

Nagayama et al. (ref. 24) further examined the tissues of patients with Yusho for their possible content

of PCDF's. Table 6 summarized their findings. Adipose tissues and liver from two ordinary persons who died of accidents contained no detectable amount (< 0.1 ppb) of PCDF's, but those from three patients with Yusho who died in 1969 or 1972 were all shown to contain PCDF's. Figures 2 and 3 show their gas-chromatograms and mass spectra. The concentration on a whole basis was 0.009 ppm on average for adipose tissues and 0.013 ppm for liver. This seems to be a rather surprising fact because in the case of PCB's the concentration on a whole basis is usually much lower in liver than in adipose tissues. When compared on fat basis, another interesting fact was noted that PCDF concentration was much higher in liver than in adipose tissue. Although the number

Table 5. Concentrations of PCB's and PCDF's and their ratios in various materials

Materials		PCB's (ppm)	PCDF's (ppm)	PCB's / PCDF's	Reference
Kanechlor-400 Yusho oil		1,000,000	ca. 20	50,000	16
	A ^a	ca. 1,000	5	200	
	B ^b	134	1.6	84	18
Patient with Yusho	Adipose tissue	1.3	0.009	144	24
	Liver	0.05	0.013	4	

^aSamples of the rice oil produced on February 5 or 6, 1968.

^bA sample of the rice oil produced on February 10, 1968.

Table 6. PCB's and PCDF's in tissues of patients with Yusho and ordinary persons

Subjects	Tissue	Case No.	Time of death	PCB's (ppm)		PCDF's (ppm)		Ratio PCB's/PCDF's	
				Whole basis	Fat basis	Whole basis	Fat basis	Whole	Fat
Yusho patients	Adipose	1	1969	1.4	3.4	0.013	0.03	108	113
		2	1969	1.3	8.5	0.006	0.04	217	213
		3	1972	1.2	2.1	0.007	0.01	171	210
		Avg.		1.3	4.7	0.009	0.003	144	157
	Liver	1	1969	0.05	4.7	0.025	2.3	2	2
		2	1969	0.06	5.6	0.010	1.1	6	5
		3	1972	0.03	3.5	0.003	0.3	10	12
Ordinary persons	Adipose	1	1975	1.0	1.4	ND	ND		
		2	1975	0.4	0.7	ND	ND		
	Liver	1	1975	0.08	1.3	ND	ND		
		2	1975	0.02	1.0	ND	ND		

UPPER :
PCDF FRACTION FROM
LIVER OF YUSHO PATIENT.
LOWER :
PCDF FRACTION FROM
YUSHO OIL.




Figure 2. Gaschromatograms of PCDF fractions from liver of patient with Yusho and from "Yusho oil."

of analyses made is quite limited and nothing can be said with certainty, this fact seems to deserve attention. As shown in table 6, these different behaviors in tissue distribution of the compounds caused a remarkable difference in ratio of PCB's to PCDF's between adipose tissues and liver. It was thus demonstrated that the concentration of PCDF's is much closer to that of PCB's in liver than in adipose tissues in patients with Yusho. The PCDF's identified in liver were mainly penta- and hexachlorodibenzofurans, containing only a trace of tetrachloroisomers.

CURRENT CLINICAL STATE OF PATIENTS WITH YUSHO

In 1974, Prof. Urabe (ref. 2), former chief of the Study Group, reported that the dermal and mucosal signs that were most marked at the incipient stage of the

poisoning had gradually been improved, while symptoms such as general fatigue, poor appetite, in constant abdominal pain, heavy headedness and headache, feeling of numbness and pain at the limbs, and cough and expectoration of sputum, all of which are considered to be due to some internal disturbances, have become more prominent year by year. In view of these tendencies together with the discovery of a characteristic gas-chromatographic pattern of PCB's remaining in the blood and tissues of patients, the diagnostic criteria for Yusho was revised in 1972 (ref. 2), as shown in table 7. As compared with the former one, the revised criteria describe briefly the dermal and mucosal lesions but newly refer to other noncutaneous objective signs and findings from several laboratory tests. It should be noted, however, that the new criteria do not refer to any specific liver function tests.




Figure 3. GC-MS of PCDF's fraction from liver of patient with Yusho (upper) and of synthesized PCDF's (lower).

Table 7. The diagnostic criteria for Yusho
(revised in October, 1972).

Yusho is considered as an acute or subacute poisoning with PCB. The general symptoms currently seen are retarded growth, neuroendocrine disturbances, phenomenon of enzyme induction, disturbances in the respiratory system, and abnormal lipid metabolism. As the local symptoms, acneform eruption and pigmentation as cutaneomucosal lesions and ocular symptoms are seen.

1. Conditions of attack
Fact of ingestion of Kanemi rice oil contaminated with PCB and familial occurrence seen in most cases.
2. General symptoms
 - a. Subjective symptoms
 - 1) general fatigue
 - 2) heavy headedness and headache
 - 3) inconstant abdominal pain
 - 4) feeling of numbness and pain at the limbs
 - 5) swelling and pain at the joints
 - 6) cough and sputum
 - 7) changes in menstruation
 - b. Objective symptom
 - 1) bronchitis-like symptom
 - 2) sensory neuropathy
 - 3) bursitis
 - 4) inhibition in growth and abnormal teeth in children
 - 5) Small-For-Dates baby and pigmentation of the entire skin of newborns
 - c. Results from clinical examination
 - 1) abnormal properties and concentration of PCB in blood
 - 2) increase of neutral lipids in blood
 - 3) anemia, lymphocytosis, hypoalbuminemia
 - 4) reduced velocity of the sensory nerve conduction and adrenocortical hypofunction
3. Cutaneomucosal signs
 - a. Acneform eruption
Black comedones and acneform eruptions which are seen at the face, buttocks, and other intertriginous sites and their suppurative tendency.
 - b. Pigmentation
Pigmentation of the face, palpebral conjunctiva, gingiva, and nails of the fingers and toes.
 - c. Ocular signs
Swelling and hypersecretion of the Meibomian gland and palpebral edema.

(Translation was made by Kuratsune)

1. Subjective Symptoms

Table 8 shows that a considerable portion of the patients are still suffering from various subjective symptoms in recent years. Kōda and Masuda examined their possible association with PCB concentrations in blood, finding no positive association at all (ref. 4). Umeda also reported on various symptoms due to disturbances of higher nervous activities (e.g., forgetfulness) complained of by most patients, but no definite association between such symptoms and the blood levels of PCB's was observed (ref. 5).

2. Dermatological Findings

Kōda and Masuda examined 72 patients with Yusho for dermatological signs and PCB levels in the blood from April 1973 to March 1974 (ref. 4). As shown in table 9, the majority of patients were still suffering from skin lesions such as pigmentation, deformation of nail, and hypersecretion of Meibomian gland even 5 years after the poisoning. They also demonstrated another important fact that group A, consisting of patients whose blood shows the gas-chromatographic pattern A, had significantly higher prevalences of dermatologic signs such as pigmentation, acneiform eruption, and deformed nails than did group B, which consisted of patients showing no such typical gas-chromatographic pattern.

Since group A had a higher average concentration of PCB's than group B, the dermal lesions seen among current patients, contrary to the subjective symptoms, seem to be causally associated with the current level or pattern of PCB's remaining in their blood. However, no conclusion could be readily made in this regard. First of all, the current excess of PCB's in the blood of patients is not remarkable in degree and is almost negligible as compared with the enormous elevation seen among the occupationally exposed workers, who nevertheless showed a rather low prevalence of dermal symptoms (table 2).

It seems rather hard, therefore, to explain the persisting dermal lesions by elevated PCB levels in blood alone. The chemical peculiarity of such PCB's and the presence of PCDF's in the bodies of current patients seem to be particularly important in this connection. However, our present knowledge does not allow us to continue discussion of the matter along this line without speculation. Furthermore, an entirely different explanation might also be possible. The skin lesions currently seen may merely be the persisting original skin lesions, the severity of which must have been determined primarily by the amount of intake of PCB's; such intake must in turn be reflected by the current PCB levels in blood of patients. According to this explanation, the

Table 8. Frequency of subjective symptoms complained by patients with Yusho from 1973 to 1974

Symptoms	Proportion ^a %
Fatigue	51.4
Headache	41.7
Phymata in articular region	8.3
Fever	2.8
Cough and sputum	56.9
Digestive disorder	40.3
Numbness of extremities	33.3
Menstrual disturbance	26.9
	(7/26)

^aCalculated by Kuratsune from original figures published by Kōda and Masuda (ref. 4).

Table 9. Prevalence of dermatological and other signs among patients with Yusho from April 1973 to March 1974, in connection with concentration and gaschromatographic pattern of PCB's in blood

Signs		Prevalence (%) ^c			
		Group A (43 cases)	Group B (26 cases)	Group C (33 cases)	Total (72 cases)
Pigmentation	Skin	51.2 ^b	0	0	30.6
	Palpebra	72.1 ^b	19.2 ^b	0	50.0
	Gingiva	95.3 ^b	57.7 ^b	66.6	80.6
	Nail	74.4 ^b	34.6 ^b	0	56.9
Acneform eruption		34.9 ^b	0 ^b	0	20.8
Comedo		34.9	23.1	0	29.2
Infection of skin		32.6	11.5	0	23.6
Deformation of nail		65.1 ^a	38.5 ^a	0	52.8
Alopecia		0	3.8	0	1.4
Disorder in teeth		18.6	7.7	0	13.9
Dypersecretion of Metbomian gland		93.0	80.8	100.0	88.9
PCB's in blood	Conc. (ppb)	7.2 ± 4.9	4.3 ± 3.1	1.7 ± 0.2	5.9 ± 4.5
	Avg. + S.D. Pattern	A ^d	B ^d	C ^d	

^aSignificant (P < 0.05) difference.

^bSignificant (P < 0.01) difference.

^cCalculated by Kuratsune from figures published by Kōda and Masuda (ref. 4).

^d"A" means the characteristic gaschromatographic pattern of PCB's remaining in the body of most patients with Yusho. "B" means gas chromatographic patterns somewhat similar to "A". "C" means patterns indistinguishable from those of normal persons.

observed association of the dermal lesions with current blood levels of PCB's is considered as a phenomenal one but not as a causal one. In order to evaluate these different possibilities, it seems essential to examine chemically and toxicologically the PCB's and PCDF's still remaining in patients' bodies.

3. Serum Triglyceride

One of the most dominant objective signs seen at the incipient stage of Yusho was a markedly increased concentration of serum triglyceride. Okumura and his associates reported recently the results of their extensive followup study on 40 patients who were examined for

serum triglyceride at least once a year successively for 6 years from 1969 to 1974 (ref. 19). As shown in table 10, a group of 14 male patients has shown no significant change in serum triglyceride levels since 1969, still maintaining levels as high as 160 ± 118 mg/100 ml even in 1974. For 26 female patients, however, a significant decrease was seen in 1973 and 1974 when compared with the levels in the previous years. However, 42 percent of them still showed higher levels than 110 mg/100 ml in 1974.

Okumura et al. (ref. 20) examined the possible association between serum triglyceride levels and PCB concentrations in blood in patients. As shown in table 11, they observed a significantly higher mean level of serum triglyceride in a group of patients who showed the characteristic gas chromatographic pattern A, as compared with other patients who did not show such a typical pattern. They also observed a significantly positive correlation between serum triglyceride levels and PCB concentrations in blood ($r = 0.485$).

Table 10. Results of followup study on serum triglyceride levels in patients with Yusho^A

Subjects	PCB's pattern	No. cases	Age mean	PCB's in blood (ppb)	Triglyceride mg/100 ml	Reference
Patients with Yusho	A	20	31.9	8.6 ± 5.2^b	134 ± 60.0^a	20
	B	14				
	C	2	21.4	3.8 ± 2.2^b	91 ± 39.8^b	
Controls	C	37	34.5	2.8 ± 1.6		
Controls					74 ± 29	19.21

^a $p < 0.05$.

^b $p < 0.005$.

Table 11. PCB's concentrations in blood and serum triglyceride levels in patients with Yusho in 1973

Patients			Triglyceride (mg/100 ml)					
			Mean $\pm$ S.D.					
Sex	Age	No.	1969	1970	1971	1972	1973	1974
Male	11 - 73	14	159 ± 57	166 ± 55	169 ± 60	174 ± 69	164 ± 68	160 ± 118
Female	7 - 59	26	155 ± 75	161 ± 70	155 ± 80	153 ± 63	129 ± 50^b	111 ± 56^b

^aCited from a report by Okumura et al. (ref. 19).

^bSignificantly lower than in 1969, 1970, 1971, and 1972 ($P < 0.05$).

Here again, a similar question can be raised in regard to such observed correlation, as already discussed in connection with the dermal lesions. Are the current elevated levels of PCB's in blood and their peculiarities in gas-chromatographic patterns causally connected with the abnormally high serum triglyceride levels found in patients? Since, as mentioned, the female patients started to decrease in serum triglyceride concentration in recent years, a followup examination of PCB's in their blood might give a good clue to answer the above question.

4. Liver of Patients with Yusho

Both PCB's and PCDF's are well-known toxic agents to the liver. PCDF's seem to be particularly toxic because a single oral administration of PCDF's as small as about 1 mg/kg could kill rabbits by severe liver necrosis (refs. 28,29). Therefore, it is reasonable to expect that patients with Yusho would have a severe liver damage. Okumura et al. (ref. 30) performed detailed medical examinations on 24 patients soon after the onset but, unexpectedly, obtained no objective findings to indicate definite liver disorders. No patients presented jaundice and only three of them had palpable livers. However, an electron microscopic examination of liver biopsy specimens conducted on a patient in February 1969 revealed a marked hypertrophy of smooth endoplasmic reticulum, indicating stimulated enzyme induction in the liver (ref. 31).

Okumura examined 38 patients with various subjective symptoms for serum enzymes, including isozymes from 1971 to 1972 (ref. 32). An increase in a fraction of lactate dehydrogenase (LDH-5) and high titers in thymol turbidity tests were observed in some of the severe cases but no definite evidence for liver disorders was obtained. Recently Hirayama et al. (ref. 33) examined 121 adult patients with Yusho and 257 healthy adult controls for serum bilirubin, demonstrating a significant lower average concentration in the patient group than in the control. They also showed significantly negative correlations between serum bilirubin and blood PCB's in concentration ($r = -0.348$, $p < 0.025$) and similarly between serum bilirubin and serum triglyceride ($r = -0.215$, $p < 0.05$). They considered that a lowered concentration of serum bilirubin in patients seemed mainly due to an accelerated bilirubin disposal from the blood.

Hirayama et al. investigated 125 patients for Australia antigen and antibody by the immunoelectrophoresis in 1971 (ref. 34). The antigen was positive in three, while the antibody was negative in all of them, indicating no difference at all in the prevalences between the patients and healthy controls. This finding seems to be important in connection with the future risk of cancer which patients might experience.

In view of all these findings, liver function tests currently available do not readily detect serious liver lesions in the patients, but it is highly desirable that adequate caution will continuously be paid to this well-known target organ of chlorinated hydrocarbons.

CHILDREN BORN TO MOTHERS WITH YUSHO

The birth of unusual babies from mothers who took "Yusho oil" during pregnancy is already well known (refs. 25,26). Their clinical features were dark brown pigmentation of the mucous membrane and the entire skin, gingival hyperplasia with pigmentation, a tendency to be small for the date, eruption of teeth at birth, hypersecretation of the Meibomian gland, and edema of the orbital area. Pigmentation of the skin disappeared in 2 to 5 months, followed by growth similar to that of normal babies.

It seems noteworthy, however, that babies with the dark brown pigmented skin continued to be born for a few years after the intake of "Yusho oil" was discontinued by mothers. Yoshimura reported on nine babies with such skin who were born to mothers with Yusho in Nagasaki prefecture from 1969 to 1972 (ref. 27). Three of such babies had been delivered by a patient from 1969 to 1971. Abe et al. (ref. 23) recently reported on PCB levels in the plasma of 30 children (aged 0-7) born to 18 mothers with Yusho in Nagasaki prefecture. Their examination was made in 1974. As shown in table 12, the PCB levels of these children were significantly higher than those of ordinary children but lower than the levels of their mothers. Their gas-chromatographic patterns of PCB's in plasma were already referred to earlier in this paper. Children fed on breast milk from mothers with Yusho tended to show a higher plasma concentration of PCB's than those who were not fed on such milk.

Yoshimura also reported an interesting case, where a baby was thought to have suffered from Yusho due exclusively to intake of PCB's through breast milk from a woman with Yusho (ref. 27). Very few data are available in regard to the concentration of PCB's in breast milk of mothers with Yusho. Masuda et al. found 0.03 - 0.06 ppm of PCB's in 5 samples of breast milk collected from a woman with Yusho within 5 days after delivery in 1973 (ref. 12). Masuda also found about 0.03 ppm of PCB's in another sample of breast milk collected a few days after a woman with Yusho delivered a baby with no dermal signs (ref. 14). The PCB levels in breast milk from patients with Yusho were therefore just within the normal range. However, the gas-chromatographic patterns of these samples were quite unique, the same as that characteristic for Yusho.

Table 12. Concentration of PCB's in plasma of children born to mothers with Yusho

Subjects	PCB's in plasma (ppb)			Ref- erence
	Subjects	Range	Mean $\pm$ S.D.	
Mothers with Yusho	18	3-33	11.2 $\pm$ 7.32	
Children born to above mothers	30	1-20	6.7 $\pm$ 4.28	23
Ordinary children	14	1-8	3.7 $\pm$ 1.97	

Table 13. Deaths seen among patients with Yusho^A

Cause of death	Number
Malignant neoplasms	9
Stomach cancer	2
Stomach cancer + liver cancer	1 ^b
Liver cancer + liver cirrhosis	1 ^b
Lung cancer	1
Lung Tumor	1
Breast cancer	1
Malignant lymphoma	2
Cerebrovascular lesion	3
Amyloidosis	1 ^b
Osteodystrophia fibrosa	1 ^b
Myocardial degeneration + pericarditis	1 ^b
Status thymicolymphaticus	1 ^b
Liver cirrhosis	1
Suicide	1
Senility	1
Traffic accidents	3
TOTAL	22

^a Cited from a report by Urage 1974 (ref. 2).

^b Autopsied cases.

MORTALITY OF PATIENTS WITH YUSHO

Omae reported in 1975 that 28 deaths occurred among 1,291 patients with Yusho up to April 30, 1975 (ref. 1). Causes of these deaths were not given, however. Urabe also reported on 22 deaths seen among 1,200 patients until September 13, 1973, and referred to their causes (ref. 2). As shown in table 13, 9 of 22 deaths were caused by malignant neoplasms, suggesting a possible excess of deaths from cancer. Since some essential information needed for epidemiological analysis is not available to us, no further reference can be made with certainty to such a possibility at the present time.

CONCLUSION

As mentioned earlier, we demonstrated the presence of PCDF's in "Yusho oil" at a much higher concentration than expected. We also showed that PCDF's are relatively more concentrated in liver. Although neither the chemical nature nor the toxicity of PCDF's contained in "Yusho oil" and in the bodies of patients are known yet, our findings clearly indicate the necessity to pay greater attention to PCDF's for clarification of the nature of Yusho. Furthermore, our studies suggested the possible formation of PCDF's from PCB's when used as heat transfer medium. Beside this, another possibility that PCDF's might be formed by heating PCB's with peroxides, which are well known to be formed during heating cooking oils, should also be investigated.

REFERENCES

1. T. Omae, "Foreword, the Fifth Report of the Study for Yusho and PCB," *Fukuoka Acta Med.*, Vol. 66, No. 10 (October 1975), pp. 547-458 (in Japanese).
2. H. Urabe, "Foreword, the Fourth Report of the Study on Yusho and PCB," *Fukuoka Acta Med.*, Vol. 65, No. 1 (January 1974), pp. 1-4 (in Japanese).
3. "Fourth Report," *Fukuoka Acta Med.*, Vol. 65, No. 1 (January 1974), pp. 1-95; "Fifth Report," *Ibid.*, Vol. 66, No. 10 (October 1975), pp. 547-648.
4. H. Koda and Y. Masuda, "Relation Between PCB Level in the Blood and Clinical Symptoms of Yusho Patients," *Fukuoka Acta Med.*, Vol. 66, No. 10 (October 1975), pp. 624-628 (in Japanese).
5. G. Umeda, "Clinical Aspects of PCB Poisoning," *Rodo no Kagaku*, Vol. 28 (1973), pp. 38-42 (in Japanese).
6. H. Kohda, S. Asahi, and S. Tshitani, "Dermatological Findings of the Patients With Yusho (PCB Poisoning) in General Examination in 1972," *Fukuoka Acta Med.*, Vol. 65, No. 1 (January 1974), pp. 81-83 (in Japanese).
7. Y. Masuda, R. Kagawa, K. Shimamura, M. Takada, and M. Kuratsune, "Polychlorinated Biphenyls in the Blood of Yusho Patients and Ordinary Persons," *Fukuoka Acta Med.*, Vol. 65, No. 1 (January 1974), pp. 25-27 (in Japanese).
8. M. Takamatsu, Y. Inoue, and S. Abe, "Diagnostic Meaning of the Blood PCB," *Fukuoka Acta Med.*, Vol. 65, No. 1 (January 1974), pp. 28-31 (in Japanese).
9. H. Hasegawa, M. Sato, and H. Tsuruta, "PCB Concentration in the Blood of Workers Handling PCB," *Rodo Eisei*, Vol. 13, No. 10 (1972), pp. 50-55 (in Japanese).
10. M. Goto and K. Higuchi, "The Symptomatology of Yusho (Chlorobiphenyls Poisoning) in Dermatology," *Fukuoka Acta Med.*, Vol. 60, No. 6 (June 1969), pp. 409-431 (in Japanese).
11. Y. Masuda, R. Kagawa, and M. Kuratsune, "Comparison of Polychlorinated Biphenyls in Yusho Patients and Ordinary Persons," *Bull. Environ. Contam. Toxicol.*, Vol. 11 (1974), pp. 213-216.
12. Y. Masuda, R. Kagawa, M. Kuratsune, "Polychlorinated Biphenyls in Yusho Patients and Ordinary Persons," *Fukuoka Acta Med.*, Vol. 65, No. 1 (January 1974), pp. 17-24 (in Japanese).
13. Committee for Investigation and Study of PCB and Others, "Study on the Distribution of Concentrations of Intracorporally Accumulated PCB" (1975) (in Japanese).
14. Y. Masuda, Unpublished data.
15. M. Asahi, H. Koda, and S. Tshitani, "Alteration in Skin Severity Grading of Yusho in the General Examination in 1973 and 1974, and Presentation of a New Standard for the Skin Severity of Yusho by Point Count System," *Fukuoka Acta Med.*, Vol. 66, No. 10 (October 1975), pp. 629-634 (in Japanese).
16. J. Nagayama, Y. Masuda, and M. Kuratsune, "Chlorinated Dibenzofurans in Kanechlor and Rice Oils Used by Patients With Yusho," *Fukuoka Acta Med.*, Vol. 66, No. 10 (October 1975), pp. 593-599.
17. J. A. G. Roach and I. H. Pomerantz, "The Finding of Chlorinated Dibenzofurans in a Japanese PCB Sample," *Bull. Environ. Contam. Toxicol.*, Vol. 12 (1974), pp. 338-342.
18. T. Kashimoto, personal communication (1975).
19. M. Okumura, M. Yamanaka, S. Nakamura, and H. Uzawa, "Consecutive Six Year Follow-up Study on Serum Triglyceride Levels in Patients With PCB Poisoning," *Fukuoka Acta Med.*, Vol. 66, No. 10 (October 1975), pp. 620-623 (in Japanese).

20. M. Okumura, Y. Masuda, and S. Nakamura, "Correlation Between Blood PCB and Serum Triglyceride Levels in Patients with PCB Poisoning," *Fukuoka Acta Med.*, Vol. 65, No. 1 (January 1974), pp. 84-87 (in Japanese).
21. H. Uzawa, A. Notomi, S. Nakamura, and Y. Ikeura, "Consecutive Three Year Follow Up Study of Serum Triglyceride Concentrations of 82 Subjects With PCB Poisoning," *Fukuoka Acta Med.*, Vol. 63, No. 10 (October 1972), pp. 401-404 (in Japanese).
22. S. Jensen and G. Sundström, "Structures and Levels of Most Chlorobiphenyls in Two Technical PCB Products and in Human Adipose Tissues," *AMBIO*, Vol. 3, No. 2 (1974), pp. 70-78.
23. S. Abe, Y. Inoue, and M. Takamatsu, "Polychlorinated Biphenyl Residues in Plasma of Yusho Children Born to Mothers Who Had Consumed Oil Contaminated by PCB," *Fukuoka Acta Med.*, Vol. 66, No. 10 (October 1975), pp. 605-609 (in Japanese).
24. J. Nagayama, Y. Masuda, and M. Kuratsune, "Polychlorinated Dibenzofurans in Tissues of Patients with Yusho," paper 330 presented at the 34th Annual Meeting of Japanese Society of Public Health, Yokohama, October 29-31, 1975, preprint, 215 pp., October 1975 (in Japanese).
25. I. Funatsu, F. Yamashita, Y. Ito, S. Tsugawa, T. Funatsu, T. Yoshikane, M. Hayashi, T. Kato, M. Yakushiji, G. Okamoto, S. Yamasaki, T. Arima, T. Kuno, H. Ida, and I. Ibe, "PCB Induced Fetopathy. 1. Clinical Observation," *Kurume Med. J.*, Vol. 19 (1972), pp. 43-51.
26. I. Taki, S. Hisanaga, and Y. Amagase, "Report on Yusho (Chlorobiphenyls Poisoning) Pregnant Women and Their Fetuses," *Fukuoka Acta Med.* Vol. 60, No. 6 (June 1969), pp. 471-474 (in Japanese).
27. T. Yoshimura, "Epidemiological Study on Yusho Babies Born to Mothers Who Had Consumed Oil Contaminated by PCB," *Fukuoka Acta Med.*, Vol. 65, No. 1 (January 1974), pp. 74-80 (in Japanese).
28. H. Bauer, K. H. Schulz, and U. Spiegelberg, "Berufliche Vergiftungen bei der Herstellung von Chlorphenol-Verbindungen," *Arch. Gewerbepath. Gewerbehyg.*, Vol. 18 (1961), pp. 538-555.
29. H. Th. Hofmann, "Neuere Erfahrungen mit Hochtoxischen Chlorkohlenwasserstoffen," *Arch. Exp. Pathol. Pharmacol.* Vol. 232 (1958), pp. 228-230.
30. M. Okumura and S. Katsuki, "Clinical Observation on Yusho (Chlorobiphenyls Poisoning)," *Fukuoka Acta Med.*, Vol. 60, No. 6 (June 1969), pp. 440-448 (in Japanese).
31. C. Hirayama, T. Irita, and T. Yamamoto, "Fine Structural Changes of the Liver in a Patient With Chlorobiphenyls Intoxication," *Fukuoka Acta Med.*, Vol. 60, No. 6 (June 1969), pp. 455-461 (in Japanese).
32. M. Okumura, "Course of Serum Enzyme Change in PCB Poisoning," *Fukuoka Acta Med.*, Vol. 63, No. 10 (October 1972), pp. 396-400 (in Japanese).
33. C. Hirayama, M. Okumura, J. Negai, and Y. Masuda, "Hypobilirubinemia in Patients With Polychlorinated Biphenyls Poisoning," *Clinica Chim. Acta*, Vol. 55 (1974), pp. 97-100.
34. C. Hirayama, M. Nakamura, and M. Yoshinari, "Australia Antigen in Patients With PCB Poisoning," *Fukuoka Acta Med.*, Vol. 63, No. 10 (October 1972), pp. 405-407 (in Japanese).

DISCUSSION

MR. ALLEN GREY (IIT Research Institute, Chicago, Illinois): Do you have any feel whether dibenzofurans concentrating in the body are more rapid in metabolism than the result of polychlorinated biphenyls?

DR. KURATSUNE: Unfortunately I have no definite idea. It is a more potent compound than PCB, I guess. I really cannot say.

DR. ORVILLE PAYNTER (EPA, Washington, D.C.): Are there any reproductive problems or irregularities continuing for many years after the ingestion of these materials?

DR. KURATSUNE: There is some disturbance of menstruation. There have been some disturbances and there have been some related problems.

MS. DEBORAH A. BARSOTTI (University of Wisconsin, Madison, Wisconsin): Were there are things that suspected any widespread gastric ulcerations or an erosion in the patients—gastric ulcers?

DR. KURATSUNE: No, I do not think so. Some of the patients had very persistent disorders of the intestines, disorders of the digestive system, but I do not know if they were suffering as a result of this or not.

VOICE: Any residual changes in the sebaceous gland during the autopsy?

DR. KURATSUNE: No, I do not know very much about it.

VOICE: I would like to ask one more question. Have you been able to specifically identify any of the dibenzofurans other than those in the body?

DR. KURATSUNE: You are asking if we could identify any of the dibenzofurans? No.

PATHOLOGICAL FINDINGS ASSOCIATED WITH CHRONIC EXPERIMENTAL EXPOSURE TO PCB's

Renate D. Kimbrough, M.D.*

Abstract

The principle organs effected by long-term exposure to commercial mixtures of polychlorinated biphenyls (PCB's) in rodents, mink, and monkeys are the gastro-intestinal tract, the liver, and the lymphatic system. Lesions of the gastric mucosa have been described in monkeys, and ulcerations of the gastric mucosa have been observed in the rat. Pathological changes in the liver in many species, such as the monkey, rodent, and mink, consist of hepatomegaly, lipid accumulation, and liver cell necrosis, particularly at higher dietary levels. Hyperchromatic nuclei and mitotic figures are noted. Ultrastructural changes in the cytoplasm of affected hepatocytes consist of an increase in smooth endoplasmic reticulum, atypical mitochondria, and accumulation of concentrically arranged membranes, which usually surround lipid vacuoles. Particularly in rodents, accumulation of a brown pigment has been observed in Kupffer cells and macrophages (ceroid pigment and uroporphyrin).

In the mouse, (male Balb/cJ strain) neoplastic nodules (hepatomas, hyperplastic nodules) developed after dietary exposure to Aroclor 1254. Female Sherman strain rats fed 100 ppm Aroclor 1260 for 21 months developed hepatocellular carcinomas as well as neoplastic nodules (hyperplastic nodules) of the livers.

In the rat and the mouse, adenofibrosis of the liver occurred after exposing rodents to either Aroclor 1254 or Aroclor 1260. Adenofibrosis, a persistent lesion, does not disappear upon cessation of exposure to the PCB's.

In connection with the persistence of the different lesions mentioned in the rodents as well as in primates, it was noted that certain homologues of the PCB mixtures fed to the animals were not eliminated from adipose tissue and liver in any appreciable amount. In rats, 6 months feeding of Aroclor 1254 at a dietary level of 100 ppm followed by a 16-month recovery period resulted in total adipose tissue levels of 152 ppm penta-, hexa-, and heptachlorobiphenyl. These animals still showed pathological changes in the liver, and liver PCB levels of 4.5 ppm.

*Toxicology Branch, Center for Disease Control, U.S. Public Health Service, Department of Health, Education, and Welfare, Atlanta, Georgia.

INTRODUCTION

For the past 45 years, polychlorinated biphenyls (PCB's) have been used in transformers, capacitors, as heat transfer fluids, and have had other industrial applications (ref. 1). The toxicity of these and related compounds has recently been reviewed (ref. 2). A number of new observations have been made since a conference was held on PCB's in 1971 and it is the purpose of this paper to outline additional findings that are associated with chronic experimental exposure of animals to PCB's.

To study the long-term toxicity of the PCB's, commercial mixtures have usually been employed. This was done for two reasons: similar mixtures were found in the environment, and the individual constituents of the PCB's are very expensive and not readily available in the quantity necessary to conduct long-term studies. Table 1 gives the composition of some of the commercial PCB mixtures. If the PCB's are given as a single dose, they are of a low order of toxicity (table 2). The acute dermal toxicity is also low. It is the repeated and often long-term exposure to these compounds that may lead to a cumulative toxic effect.

HEPATOTOXICITY

Dietary exposure of rats to the PCB's produces enlargement of the liver cells in some adult rats at a dietary level of 5 ppm (0.4 mg/kg/day) (ref. 3). Liver weights were increased in 21-day-old F₁ male weanlings when the dams were fed as little as 1 ppm of Aroclor 1254 (ref. 3). At a dietary level of 20 ppm or above of Aroclor 1254 or 1260, which is equivalent to a dietary intake of 1.5 mg/kg/body weight per day, for an extended period of time, the hepatocytes in many rats had foamy cytoplasm consistent with lipid accumulation. In addition, hyperchromatic nuclei and binucleation was observed in many liver cells. Inclusions were present in the cytoplasm of the liver cells. These inclusions on electron microscopic examination were consistent with concentrically arranged membranes surrounding lipid vacuoles. Other ultrastructural changes observed at this and higher dietary levels in rats consisted of an increase in smooth endoplasmic reticulum and atypical mitochondria. These ultrastructural changes have also been described in primates (ref. 4) and are known to occur with a number of other xenobiotics. Similar observations were made in a study with smaller numbers of animals

Table 1. Typical percentage composition of polychlorinated biphenyl products^a

Homologue # Cl/biphenyl	Aroclor 1221	Aroclor 1016	Aroclor 1242	Aroclor 1254
0	11	<0.1	<0.1	<0.1
1	51	1	1	<0.1
2	32	20	16	<0.5
3	4	57	49	1
4	2	21	25	21
5	<0.5	1	8	48
6	ND ^b	<0.1	1	23
7	ND	ND	<0.1	6

^aPercent (w/w) by GC/mass using area correction factors by homolog response, (Papageorge, written communication, June 1973).

^bNone detected; <0.01% = ND.

Table 2. The incidence and type of liver lesions in female sherman strain rats

Type of Lesion	Incidence	
	Controls	Experimental
Hepatocellular carcinoma	1/173	26/184
Neoplastic nodules	0/173	144/184
Foci or areas of cytoplasmic alteration	28/173	182/184

where the rats were fed Aroclor 1242 and Aroclor 1016 (ref. 6).

A brown pigment representing ceroid pigment and uroporphyrin was observed in Kupffer cells and macrophages. Particularly at higher dietary levels, livers showed pink fluorescence under UV lights.

In addition, exposure of rats and mice to PCB's for 6 months or longer produced grayish white lesions in the liver. On microscopic examination, these lesions consisted of proliferation of glandular epithelial cells that formed ducts and were surrounded by very pronounced fibrosis (refs. 6,7). The ducts often contained cellular debris. This lesion, called adenofibrosis, was first described by Edwards and White (ref. 8) in rats fed the carcinogen butter yellow (P-dimethylaminoazobenzene).

When rats were exposed for 6 months to a dietary intake of 500 ppm Aroclor 1254 and then sacrificed first at monthly and then at bimonthly intervals, the adenofibrosis persisted through a 10-month observation period. Usually adenofibrosis in rodents occurs concomitantly with hepatocellular carcinomas and/or neoplastic nodules (hyperplastic nodules). This was true for the Balb/cJ mouse (ref. 7). When 50 Balb/cJ inbred male mice were fed 300 ppm Aroclor 1254 (49.8 mg/kg/bodyweight per day), a total of 10 neoplastic nodules (hyperplastic nodules) were found in 9 per 22 surviving mice after 11 months of exposure to the experimental diet. No tumors were found in 58 surviving controls.

In another study, 400 weanling 21- to 28-day-old Sherman strain COBS female rats were distributed into two groups of 200 animals according to a table of random numbers. The animals were housed 10 rats per cage. Two hundred rats were fed plain ground purina chow and 200 rats were fed the same diet containing 100 ppm Aroclor 1260. This study was only conducted at this dietary level and with female rats because in a preliminary feeding study, a bladder tumor was found in 1 of 10 female rats fed 100 ppm Aroclor 1260 (ref. 8). The food consumption of the rats and their bodyweights were determined at intervals. A slight decline in the rate of the weight gain of the test group compared with the control group began about 3 months after onset of the experiment. Mean final bodyweights were 420 grams for the control group and 392 grams in the test group. This difference was statistically significant ($P < 0.001$) since such a large group of animals was involved in this study. The food consumption of rats declines with age. Accordingly, PCB intake declined from 11.8 mg/kg/day during the first week of exposure to 6.1 mg/kg/day at 3 months of exposure and to 4.3 mg/kg/day at 20 months. We determined the PCB concentrations in the experimental diet at intervals and these ranged usually from 70 to 107 ppm. We also spot checked the diet for aflatoxins. Afl-

toxins were never detected in either the control or the experimental diet. A total of 173 control and 184 experimental animals survived to the age of 21-23 months. At autopsy of these rats, a consistent difference in the appearance of the livers was observed between the experimental and the control groups. Almost all (170 of 184 livers) of the experimental animals had from a few to multiple elevated tan nodules on the liver surface. Additional nodules were usually seen on sectioning. These nodules varied from .1 to several centimeters in diameter. In contrast, the liver of only one control animal showed gross abnormalities and was markedly enlarged, nodular, tan, and firm. A variety of tumors of other organs was observed in both the experimental and the control group but a difference in the incidence of tumors in other organs in the experimental and the control group did not exist.*

Histologic examination of the liver showed that 26 experimental rats and 1 control rat had hepatocellular carcinomas. An additional 144 experimental animals had hepatocellular nodules consistent with neoplastic nodules (hyperplastic nodules). In addition, 182 treated and 28 control animals had areas of hepatocytes with altered cytoplasm. The cells in these areas were often similar to those that were observed in the neoplastic nodules but the architecture of these atypical areas in the liver was the same as that of normal liver tissue and the liver plates merged with the surrounding liver tissue rather than compressing it.

In classifying the different liver lesions, the recommendations made in a liver tumor workshop (ref. 9) were followed.

The results of this bioassay test illustrate that Aroclor 1260 produces hepatocellular carcinomas according to traditional histological criteria and neoplastic nodules, which are a part of the spectrum of a response to hepatocarcinogenic agents. Neoplastic nodules must be included in the evaluation of tumorigenesis. Neoplastic lesions of the liver have also been produced by some of the commercial Japanese PCB mixtures; in mice with Kanechlor 500, and in Donryu rats with Kanechlor 400 (refs. 10,11).

The effect on the gastric mucosa as it has been described in primates (ref. 4) does not seem to be as prevalent in rodents. Only very high dietary levels, such as single doses of 3,000 mg/kg, will cause alteration of the gastric and duodenal mucosa (ref. 2). Primates (ref. 4) receiving 100 to 300 ppm Aroclor 1248 developed thickened gastric mucosa that contained numerous large cysts filled with mucin. Extension of the atypical

*About 40 percent of the rats in each group had extra-hepatic tumors. In a number of the rats, multiple tumors were present.

appearing glandular epithelium into the muscularis mucosa and the underlying submucosa was also noted. This hyperplastic gastritis was quite persistent in the primate.

In conjunction with some of the feeding studies in rodents, tissue levels were determined in adipose tissue and the liver. It was noted that the gas chromatograms of the PCB's that were extracted from tissues was quite different from gas chromatograms of the standards. The PCB compounds remaining in adipose tissue as well as liver even after dietary exposure to PCB's has been terminated for as long as 10 or 16 months were the penta-, hexa-, and heptachlorobiphenyls, with molecular weights of 324, 358, and 382 (ref. 8). When rats were fed Aroclor 1254 at a dietary level of 100 ppm for 6 months, and were then removed from exposure to PCB's for 16 months, levels of 4.4 ppm of PCB-derived material was present in the liver and 152 ppm of PCB-derived material in adipose tissue on a wet weight basis. The livers of these rats showed some of the morphological changes already described (ref. 12). In primates that consumed Aroclor 1248 and reached adipose tissue levels of 127 ppm, after an 8-month recovery period the adipose tissue levels were 34 ppm of PCB-derived materials (ref. 4).

SUMMARY

The administration of PCB's to animals—particularly rodents but also monkeys and mink—produces a variety of responses in the liver. Early enlargement of the liver is primarily due to hypertrophy of the cells and an increase of the smooth endoplasmic reticulum of the cytoplasm of the liver cells. The smooth endoplasmic reticulum may condense in the liver cells and form hyalin inclusions, which on electron microscopic examination consist of concentrically arranged membranes containing lipid vacuoles. In addition to these lipid vacuoles, lipid accumulation may also occur throughout the liver cells. These changes are initially reversible. However, if the exposure to PCB's is continued, then liver damage, including liver cell necrosis, may also develop. This is accompanied by proliferation of the liver cells resulting in pleomorphism. Long-term exposure to PCB's in rodents produces a tumorigenic response which consists of the development of atypical areas, neoplastic nodules, and hepatocellular carcinoma. Adenofibrosis, which usually occurs concomitantly with hepatocellular carcinomas, has also been produced in the rat and the mouse. Pigment deposition within the macrophages and Kupffer cells has been noted (ref. 8). This pigment is composed of ceroid pigment (lipofuchsin) and uroporphyrin. Hemosiderin may also be present. In addition to liver

changes, hyperplasia of the gastric mucosa has been observed in the primates (ref. 4) following the exposure to PCB's.

Because of these findings in experimental animals, ingestion of PCB's in humans must be curtailed. Exposure from all sources in the occupational environment needs to be reviewed and workers with long-term occupational exposure to PCB's should be studied. An effort should be made to establish all environmental sources of PCB's in order to assess exposure of the general population.

REFERENCES

1. M. G. Broadhurst, "Use and Replaceability of Polychlorinated Biphenyls," *Environ. Health Perspect.*, No. 1 (1972), pp. 81-102.
2. R. D. Kimbrough, "The Toxicity of Polychlorinated Polycyclic Compounds and Related Chemicals," *CRC Crit. Rev. Toxicol.*, Vol. 2 (1974), pp. 442-498.
3. R. E. Linder, T. B. Gaines, and R. D. Kimbrough, "The Effect of Polychlorinated Biphenyls on Rat Reproduction," *Ed. Cosmet. Toxicol.*, Vol. 12 (1974), pp. 63-77.
4. J. R. Allen, "Response of the Nonhuman Primate to Polychlorinated Biphenyl Exposure," *Federation Proc.*, Vol. 34, No. 8 (1975), pp. 1675-1678.
5. V. W. Burse, R. D. Kimbrough, E. C. Villanueva, R. W. Jennings, R. E. Linder, and G. W. Sovocool, "Polychlorinated Biphenyls, Storage, Distribution, Excretion and Recovery: Liver Morphology after Prolonged Dietary Ingestion," *Arch. Environ. Health*, Vol. 29 (1974), pp. 301-308.
6. R. D. Kimbrough, R. E. Linder, V. W. Burse, and R. W. Jennings, "Adenofibrosis in the Rat Liver," *Arch. Environ. Health*, Vol. 27 (1973), pp. 390-395.
7. R. D. Kimbrough and R. E. Linder, "Induction of Adenofibrosis and Hepatomas of the Liver in Balb/c Mice by Polychlorinated Biphenyls (Aroclor 1254)," *J. Natl. Cancer Inst.*, Vol. 33 (1974), pp. 547-552.
8. R. D. Kimbrough, R. A. Squire, R. E. Linder, J. D. Strandberg, R. J. Montali, and V. W. Burse, "Induction of Liver Tumors in Rats by Polychlorinated Biphenyl Aroclor 1260," *J. Nat. Cancer Institute*, December 1975, in press.
9. R. A. Squire and M. H. Levitt, "Report of a Workshop on Classification of Specific Hepatocellular Lesions in Rats," *Cancer Research*, Vol. 35 (1975), pp. 3214-3223.
10. N. Ito, H. Nogasaki, M. Arai, et al., "Histopathologic Studies on Liver Tumorigenesis Induced in Mice by

Technical Polychlorinated Biphenyls and its Promoting Effect on Liver Tumors Induced by Benzene Hexachloride," *J. Natl. Cancer Institute*, Vol. 51 (1973), pp. 1637-1648.

11. N. T. Kimura, and T. Baba, "Neoplastic Changes in the Rat Liver Induced by Polychlorinated Biphenyl," *Gann*, Vol. 64 (1973), pp. 105-108.
12. R. D. Kimbrough, V. Burns, R. E. Linder, and R. Jennings, personal communication, unpublished material.

DISCUSSION

MR. LAWRENCE ROY: You indicated after an animal has been exposed for 6 months you get regression, and if they did regress...

DR. KIMBROUGH: I don't know if I can answer all of that; you may have to repeat part of your question. But, first of all, I think in the studies that I did—and we really haven't got any time to go into all of this this morning—if you feed animals for only 6 months you do not see any tumors; you have to feed animals PCB's for much longer periods of time.

The first indication of any tumor development that I saw in reproduction studies we did was when the animals were exposed for at least 300 days. On the other hand, in the rat you do get what I call adenofibrosis if you feed the animals for about 6 months. That lesion is also known as cholangiofibrosis. Adenofibrosis does not regress. We did a feeding study where you feed the animals for 6 months, and then sacrifice them at bimonthly intervals, and the lesion will still be there 10 months later. So this is one problem with PCB's.

And at least some of the PCB homologs are retained for such a long period of time that I don't know whether you could also have what you might call internal exposure.

I think you had some other questions?

VOICE: First of all, do tumors cause death in these animals, and do these tumors cause an increase in size?

DR. KIMBROUGH: Some of the animals I think have died with large tumors at the end of the study. I don't think the tumors that are called hepatocellular

carcinomas would regress. I also did not say that we had any regression in the animals we fed for 6 months.

MS. DIANE HORVAK (University of Wisconsin, Department of Pathology): What was the difference between the carcinoma and the nodule?

DR. KIMBROUGH: We did use histological criteria. In our classification, the tumors that we call neoplastic nodules were well circumscribed tumors that would extend over several lobules and some of them were actually quite large, and would compress the surrounding normal liver tissue, and because of that, they were circumscribed.

The lesions that were classified as carcinomas showed disorganized liver. Liver plates were two or three layers thick. You would have dilated sinusoids, would see mitotic figures and a great deal of pleomorphisms, but none of these tumors metastasized.

CHAIRMAN RALL: There's a question over there.

DR. ROBERT RISEBROUGH (University of California): Since we now know that these PCB preparations do contain dibenzofurans, I wonder if it is your plan to repeat these experiments with PCB's that do not contain the dibenzofurans. I wonder also if you would care to guess whether these tumors are caused by PCB or by the contaminants.

DR. KIMBROUGH: I have no plans at the moment to repeat these experiments. I do not know if I could get a completely clean Aroclor 1260.

The PCB that we used was Aroclor 1260 with the lot number AK3, which Dr. Bowes has analyzed; I think the level of the combined furans in that particular sample is less than 1 ppm. I may be wrong there, but if you recalculate that, you will find that the amount of furans consumed by the animals was very small. The amount of PCB's which the animals ingested was 5 mg/kg body weight/day, and the furans constituted less than 1 ppm of that. This amount is so small that I wonder whether it had any effect in this particular experiment.

CHAIRMAN RALLS: We'll come back to the issue of dibenzofurans later.

SUMMARY OF TOXICOLOGICAL STUDIES ON COMMERCIAL PCB's

J. C. Calandra, M.D., Ph.D.*

Abstract

A broad toxicological program was conducted to evaluate the biological effects of Aroclor 1242, 1254, and 1260 in mammalian as well as avian species. No-effect levels were defined which permit an assessment of the hazard these materials present to man and his environment.

The urgent need for additional toxicological data became apparent when the refinement of analytical techniques made possible the identification of PCB's in many portions of the ecosystem.

To assess the biological hazards of these materials, chronic feeding studies in rats and dogs were conducted according to accepted traditional procedures with Aroclors 1242, 1254, and 1260. It should be pointed out that Aroclor 1260 is no longer produced in this country since it does not meet the physical specifications for its restricted uses (ref. 1).

In addition, three-generation two-litter reproduction and teratology studies in albino rats as well as a dominant lethal mutagenic study in albino mice were considered to be necessary for the broad spectrum safety evaluation of these materials.

Effects such as decreases in eggshell thickness described in certain avian species suggested that toxicity and reproduction studies in chickens would be helpful in evaluating possible untoward effects in birds. A list of the studies conducted are presented in table 1.

The experimental design of the chronic rat and dog studies is given in tables 2 and 3. It should be noted that these studies were of typical Food and Drug Administration design for the evaluation of the safety of direct and indirect food additives.

The important results in the chronic rat studies which were conducted on Charles River rats are summarized briefly in tables 4, 5, and 6.

Food consumption, mortality, and hematologic, urine, and blood chemistry studies did not differ among treatment and control groups. The only weight depression observed was at the 24-month point in females fed 100 ppm of Aroclor 1254.

Liver weight increases were noted in males and females fed 100 ppm Aroclor 1254 or Aroclor 1260, and in females only in the 100 ppm group fed Aroclor 1242.

As expected, the important histopathologic changes in the rat study were present in the livers of the 24-month sacrifice animals and consisted of hepatocellular alterations such as focal hypertrophy, cytoplasmic lipid changes and in some animals at 100 ppm, hepatomas or cholangiohepatomas. No evidence of hepatocellular carcinogenicity of the Aroclors was found in this study.

The conclusion that "no evidence of hepatocellular carcinogenicity of the Aroclors was found in this study" was reached only after extensive reevaluation of the original liver slides as well as additional liver sections from all of the animals after the Kimbrough results on Aroclor 1260 became known to us (ref. 2).

The slides were read independently and separately by Dr. Donovan Gordon (ref. 3), Professor Ward Richter (ref. 4), and Professor P. Pour (ref. 5) of Industrial BIO-TEST Laboratories, the University of Chicago, and the Eppley Institute for Cancer Research, respectively.

The interpretation of pathologic changes that occur in the liver as a result of absorption of chlorinated hydrocarbons is a key issue that needs resolution by the community of pathologists (ref. 6, 7). The problem is highlighted in the context of PCB's since there appears to be disagreement as to whether Aroclor 1260 is or is not a hepatocellular carcinogen (ref. 8). Pour reevaluated the Kimbrough slides and does not agree with the reported findings.

The findings in the chronic dog study are summarized in table 7. The feeding of Aroclor 1260 at 100 ppm showed an increase in serum alkaline phosphatase activity and liver weights. A slight decrease in body weight gain was noted at the 100 ppm dose level in males and at 10 and 100 ppm in females. No remarkable histopathologic changes were found.

The design of the dominant lethal mutagenic study is presented in table 8. No effects related to Aroclor treatment were seen in the parameters listed in table 9—mortality, mating index, number of implantation and resorption sites, number of viable embryos, preimplantation loss or mutation rates. This finding is in agreement with that of Green et al. (ref. 10).

No effects related to Aroclor treatment were seen in the parameters listed in table 9—mortality, mating index, number of implantation and resorption sites, number of viable embryos, preimplantation loss or mutation rates. This finding is in agreement with that of Green et al. (ref. 10).

*Industrial BIO-TEST Laboratories, Inc., Northbrook, Ill., note.

The standard design for a three-generation two-litter reproduction study in albino rats is given in table 10 and the teratology study in table 11. A brief summary of the results (table 12) indicates that none of the Aroclors studied produced adverse effects in the two litters of the first generation.

All progeny delivered by female rats in each of three generations exposed to dietary levels of up to 100 ppm of either Aroclor 1242, 1254, or 1260 were structurally normal. A reduction in the mating index was observed in the second and third generations of animals fed either 10 or 100 ppm. The ability of females to conceive, carry the delivery process to parturition, and to successfully nourish the young was not affected by the three Aroclors. It should be stressed that no changes in the reproductive tract of either male or female rats were produced by any of the three Aroclors. Findings in the third generation were similar to those in the first with no suggestion of any alterations in response as a function of succeeding generations.

Teratologic studies in which albino rats were exposed to either Aroclor 1242, 1254, or 1260 at doses of up to 30 mg/kg during rapid organogenesis—gestation days 6 through 15—were conducted in our laboratories. No evidence of embryotoxicity as reflected by an increase of fetal resorption or teratogenicity as measured by complete external, skeletal, and internal evaluation of fetuses obtained from the Aroclor-treated females, was obtained. Other experimental data pertaining to the potential teratogenicity of polychlorinated biphenyls supports the lack of adverse effects. Mizunuya (ref. 11) and his colleagues found no evidence of teratogenicity in the rat when fed at dietary levels of up to 250 ppm. In the mouse, Toeruek (ref. 12) found that doses of up to 500 mg/kg were nonteratogenic although when given on gestation days 1 through 6 a decrease in implantation sites and fetal weights was observed. These doses given on gestation days 7 through 11 failed to produce any changes with respect to either reproductive parameters or teratogenicity. Further, no evidence of malformation was obtained in infant monkeys delivered to females fed either 2.5, 5, or 25 ppm Aroclor 1248 although the birth weights were reported to be reduced (ref. 9).

The last study in this series was a toxicity/reproduction study in white leghorn chickens (tables 13, 14, and 15).

Aroclor 1260 at all test levels did not produce adverse effects on the various parameters investigated. Egg production in hens fed 100 ppm Aroclor 1242 or 1254 was decreased as was egg hatchability. In fact, poor hatchability of eggs from hens fed 8 ppm Aroclor 1242 was found (table 15).

In addition, Aroclor 1242 at 10 and 100 ppm and

Aroclor 1254 at 100 ppm were associated with reduced eggshell thickness. Chick viability was affected by both substances at the 10 ppm dose level.

CONCLUSIONS

1. The no-effect level for the Aroclors in the chronic rat and dog studies is about 10 ppm.
2. No teratogenic or mutagenic effects were found.
3. No hepatocellular carcinomas were present.
4. The no-effect level in the rat reproduction study is between 1 and 10 ppm and is the result of low mating indices.
5. In the chicken reproduction and teratology studies, effects were more severe with Aroclor 1242 with the no-effect level being 2 to 4 ppm.

REFERENCES

1. Private communication, Monsanto Company.
2. R. D. Kimbrough et al., *Induction of Liver Tumors in Rats by Polychlorinated Biphenyl Aroclor 1260*, in press.
3. D. E. Gordon, report on Histopathological Evaluation of Aroclor 1242, 1254, and 1260, March 24, 1975.
4. Ward R. Richter, report on Histopathological Evaluation of Aroclor 1242, 1254, and 1260, March 24, 1975.
5. Report on Histopathological Reevaluation of Livers for Rats Treated with Aroclors, August 1, 1975, by P. Pour.
6. R. A. Squire et al., "Report of a Workshop on Classification of Specific Hepatocellular Lesions in Rats," *Cancer Research*, Vol. 35 (1975), p. 3214.
7. Subcommittee on Environmental Carcinogenesis of the National Cancer Advisory Board, November 10-11, 1975.
8. P. Pour, report on Histopathological Reevaluation of Tissues from Female Sherman Rats Fed Aroclor 1260, October 31, 1975.
9. J. R. Allen, "Response of the Nonhuman Primates to Polychlorinated Biphenyl Exposure," *Fed. Proc.*, Vol. 34 (July 1975), p. 1675.
10. S. Green et al., "Lack of Dominant Lethality in Rats Treated with Polychlorinated Biphenyls (Aroclors 1242 and 1254)," *Fed. Cosmet. Toxicol.*, Vol. 13 (1975), p. 507.
11. Y. Mizunuya et al., "Effects of PCB's on Fetuses and Offspring in Rats," *Shakuhin Eisigaku Zasshi*, Vol. 15 (1975), p. 252.
12. P. Toeruek, "Effects of PCB on the Developing Mouse," *Chemosphere*, Vol. 2 (1973), p. 173.

DISCUSSION

MR. PAUL ARGENTINE: You didn't find any effects or pathological agents in the dog?

DR. CALANDRA: Would you repeat that?

MR. ARGENTINE: How did you arrive at the no-effects level in canine at 10 ppm? In studies you showed no pathological agents and no toxicity?

DR. CALANDRA: As I indicated, this is a very brief and rapid summary. We have a question about liver weights and one or two other parameters and to be conservative, we have used the number of 10 ppm. In other words, we are not in any way indicating

that PCB's are nontoxic materials, and this is a conservative estimate.

DR. ALLEN GREY (I.I.T. Research, Chicago, Illinois): Are you able to relate the differences in biological effects on the various Aroclors to their composition?

DR. CALANDRA: Only generally. As everyone knows, the higher chlorinated materials appear to be more persistent in the mammalian system. And there appears to be a target organ—the liver—which appears to be more susceptible to the higher chlorinated materials. I think these are the only generalizations you can make at this time.

Table 1. Toxicity studies conducted with Aroclors 1242, 1254 and 1260

Type of test	Test animal
Two-year chronic oral	albino rats
Two-year chronic oral	beagle dogs
Three-generation reproduction	albino rats
Teratology	albino rats
Dominant lethal mutagenic	albino mice
Toxicity/reproduction	white leghorn chickens

Table 2. Two-year chronic oral toxicity study--albino rats and beagle dogs

Test material	Dietary levels (ppm)			Number of animals per dietary level			
				rats		dogs	
				M	F	M	F
None	-	-	-	50	50	4	4
Aroclor 1242	1,	10,	100	50	50	4	4
Aroclor 1254	1,	10,	100	50	50	4	4
Aroclor 1260	1,	10,	100	50	50	4	4

Table 3. Two-year chronic oral toxicity study--albino rats and beagle dogs

Parameters investigated:

- Body weight
- Food consumption
- Hematology
- Clinical blood chemistry (BUN, SAP, SGPT, fasting blood glucose, SGOT--dogs only)
- Urinalyses
- Pathology (gross, organ weights, microscopic)

Table 4. Ingestion of Aroclor 1242 by albino rats--liver effects

Increase in liver weights--100 ppm--females

Primary liver lesions

None at 3-, 6-, 12-month sacrifice

24-month sacrifice--100 ppm--increased incidence of:

Nodular hyperplasia	(8/20)
Hepatoma	(2/20)
Chologiohepatoma	(1/20)
Hepatocellular carcinoma	(0/20)

Table 5. Ingestion of Aroclor 1254
by albino rats--liver effects

Increase in liver weights--100 ppm	
Primary liver lesions	
None at 3-, 6-, 12-month sacrifice	
24-month sacrifice--100 ppm-- increased incidence of:	
Modular hyperplasia	(13/27)
Hepatoma	(4/27)
Cholangiohepatoma	(2/27)
Hepatocellular carcinoma	(0/27)

Table 6. Ingestion of Aroclor 1260
by albino rats--liver effects

Increase in liver weights--100 ppm	
Primary liver lesions	
None at 3-, 6-, 12-month sacrifice	
24-month sacrifice--100 ppm-- increased incidence of:	
Modular hyperplasia	(7/27)
Hepatoma	(5/27)
Cholangiohepatoma	(2/27)
Hepatocellular carcinoma	(0/27)

Table 7. Effects of ingestion of
Aroclors--beagle dogs

Test material	Effect
Aroclor 1242	no effects
Aroclor 1254	slight decrease in body weight gain --100 ppm
Aroclor 1260	slight decrease in body weight gain --100 ppm, males --10 and 100 ppm, females increase in SAP-- 100 ppm increase in liver weights--100 ppm

Table 8. Dominant lethal mutagenic
study--albino mice

Test material	Dose*
Corn oil	0.9 ml/kg
Methyl methane sulfonate (MMS)	100 mg/kg
Aroclor 1242	500 or 1000 mg/kg
Aroclor 1254	500 or 1000 mg/kg
Aroclor 1260	500 or 1000 mg/kg

*Single dose given i.p. to 12
males/group.

Table 9. Dominant lethal mutagenic study--albino mice

No effects related to Aroclor treatment seen in:

- Mortality
- Mating index
- Number of implantation sites
- Number of resorption sites
- Number of viable embryos
- Preimplantation loss
- Mutation rates

Table 10. Three-generation reproduction study^a--albino rats

Test material	Dietary levels (ppm)			Number of animals per dietary level	
				M	F
None	-	-	-	8	16
Aroclor 1242	1,	10,	100	8	16
Aroclor 1254	1,	10,	100	8	16
Aroclor 1260	1,	10,	100	8	16

^aTwo litters per generation.

Table 11. Teratology study--
albino rats

Test material	Dose ^a (mg/kg/day)	Number of gravid rats
Corn oil	-	26
Aroclor 1242	10 or 30	26
Aroclor 1254	10 or 30	26
Aroclor 1260	10 or 30	26

^aAdministered on gestation days 6
through 15 (10 doses).

Table 12. Effect of Aroclors on
reproduction/teratology--
albino rats

1. Reproduction study
 - First generation--no effects
 - Second and third generations--
10 and 100 ppm
 - decrease in mating index
 - decrease in incidence of
pregnancy
 - (Aroclor 1242--no third genera-
tion with 100 ppm).
2. Teratology study--no effects.

Table 13. Toxicity/reproduction
study--white leghorn chickens

Test material	Dietary levels (ppm)	Number of animals per dietary level	
		M	F
None	-	8	40
Aroclor 1242	1, 2, 4, 8, 10, 100	4	20
Aroclor 1254	1, 10, 100	4	20
Aroclor 1260	1, 10, 100	4	20

**Table 14. Toxicity/reproduction
study--white leghorn chickens**

Parameters investigated:

Body weight
Food consumption
Egg production
Egg quality
Egg hatchability
Eggshell thickness
Chick body weight
Chick viability
Pathology

**Table 15. Effects of Aroclors
on chicken reproduction**

Parameter	Dietary level 1242	Causing effect 1254
Egg production	100	100
Egg hatchability	8	100
Shell thickness	100	100
Chick viability	10	10
Aroclor 1260--no effects at any dose level		

PATHOBIOLOGICAL RESPONSES OF PRIMATES TO POLYCHLORINATED BIPHENYL EXPOSURE

J. R. Allen, D.V.M., Ph.D., and D. H. Norback*

Abstract

Male and female rhesus monkeys received varying levels of polychlorinated biphenyls (PCB's) and were evaluated for toxic effects, reproductive dysfunctions, and metabolism of the compounds. Female rhesus monkeys exposed to dietary levels as low as 2.5 and 5.0 ppm of PCB (Aroclor 1248) developed facial acne, erythema, subcutaneous edema, conjunctivitis, and loss of eyelashes. Reproductive dysfunctions were manifested by irregular menstrual cycles, early abortions, and stillbirths. As a result of transplacental migration of the compounds, all infants born of PCB-exposed animals contained PCB's in their tissues at birth. The infants, which continued to be exposed to PCB's by ingestion of milk from their lactating mothers, developed skin lesions and 50 percent expired within 4 months.

Metabolic studies demonstrated 90 percent absorption of the PCB's from the gastrointestinal tract and distribution in organs of high lipid content. Hydroxylated metabolites were formed in the liver and excreted through the biliary and urinary routes. Lower chlorinated congeners were more rapidly metabolized and excreted, while concentrations of the highly chlorinated biphenyls persisted in the adipose tissue in excess of 2-1/2 years. The detection of the urinary metabolite trans-3,4-dihydro-3,4-dihydroxy-tetrachlorobiphenyl suggests that the mechanism of metabolism is through an arene oxide intermediate. In vivo and in vitro studies demonstrated binding of PCB's with macromolecules.

INTRODUCTION

Even though the polychlorinated biphenyls (PCB's) have been used extensively for various industrial purposes for the past 40 years, the health significance of

human exposure to these compounds only recently has become of widespread concern. The scientific community was alerted to the potential environmental health problem by Jensen in 1966 (ref. 1) after PCB's were identified in tissue extracts of birds experiencing reproductive difficulties in Sweden. The magnitude of the problem was brought to the forefront by the "Yusho" incident when over 1,000 Japanese suffered prolonged ill effects from exposure to PCB-contaminated rice oil (ref. 2). Further concern about the potential danger of PCB's on human health followed disclosure of increasing levels of these compounds in various foods. The contamination has been attributed to incorporation of these compounds within the food chain or from packaging of food products in PCB-impregnated paper containers (ref. 3). Increasing levels of PCB's in human tissue samples attest to the magnitude of the human exposure (refs. 4,5).

Within this laboratory various animal models, including the nonhuman primate and rodent, have been evaluated following exposure to PCB's for the development of lesions which parallel those recorded in man. Emphasis has been placed on determining pathophysiological alterations that arise in animal models as a result of exposure to several levels of PCB's for variable periods of time. The absorption, tissue distribution, and rate of excretion of PCB's have been determined. The interaction of the PCB's or their metabolites with cellular macromolecules has also been a major area of investigation. The following report, which includes previously unpublished observations, presents a summary of the progress that has been made in this laboratory on the above mentioned areas of PCB research.

GENERAL EFFECTS OF PCB'S ON NONHUMAN PRIMATES

The investigation of toxicity produced by PCB's in various animal species demonstrated the limitations of rodents as animal models. Male Sprague-Dawley rats were able to survive for 1 year on diets containing 100 ppm PCB (Aroclor 1248, 1254, or 1262) without showing signs of illness (ref. 6). These observations substantiated those of Keplinger et al. (ref. 7). Increasing the PCB content of the rat diets to 1,000 ppm did not produce skin lesions; however, death occurred within 6 to 8 weeks due to widespread hepatic degeneration (ref. 8).

Male rhesus monkeys developed many of the signs

*Department of Pathology and Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin. This investigation was supported in part by U.S. Public Health Service grants ES-00472, ES-00956 and RR-00167 from the National Institutes of Health, and the University of Wisconsin Sea Grant Program. The majority of the data presented in this report were obtained through the efforts of our colleagues in the Experimental Pathology Laboratory: D. Barotti, K. Blomquist, L. Carsons, I. C. Hau, R. Marier, L. Moore, D. Peterson, J. Seymour, J. Van Miller. A portion of this research was conducted in the University of Wisconsin-Madison Biotron, a controlled environmental research facility supported by the National Science Foundation and the University of Wisconsin.

experienced by humans that had been inadvertently exposed to PCB's. Monkeys fed diets containing 100 and 300 ppm PCB (Aroclor 1248) (table 1) developed facial edema, erythema, acne, and alopecia within 3 weeks. The lesions became progressively more severe with increased length of exposure (refs. 9,10). In addition, the animals developed anorexia, loss in weight, hypoproteinemia, hypolipidemia, and anemia. Within 3 months the majority of the monkeys had died or were moribund. Necropsies of these animals revealed decided mucosal gastric hyperplasia with penetration of the glandular epithelium into the underlying submucosa (ref. 10). Numerous ulcerations of the hyperplastic gastric mucosa were also present (ref. 11). In addition, there was a decided hypertrophy of the liver.

Female monkeys fed 25 ppm PCB (Aroclor 1248) (table 1) in the diet developed facial lesions similar to those observed in the animals receiving higher levels of PCB's (ref. 12). After 2 months on the PCB diet it was necessary to discontinue the exposure due to the severity of intoxication. One of the six experimental animals died 4 months after the initial exposure to PCB's. Necropsy evaluation demonstrated severe gastric hyperplasia and ulceration. The surviving adult female monkeys continued to be devoid of eyelashes and displayed facial acneform lesions 2 years following exposure to the PCB's. Infants born to these females were small (350 vs. 450 g) and contained PCB's in their tissues at birth.

Female monkeys given 2.5 and 5.0 ppm PCB (Aroclor 1248) (table 2) in their diets developed facial edema, swollen eyelids, erythema, loss of hair, and acne within 2 months (ref. 13). By the fourth month, irregularities in the menstrual cycles and an increased level of urinary ketosteroids were recorded (ref. 14). Following 6 months of PCB exposure the female monkeys were bred to control males. Six of eight animals on the 5.0 ppm diet conceived (table 2). The remaining two were bred on five separate occasions without conceiving. Four of the six females experienced abortion early in gestation. Eight of eight of the 2.5 ppm PCB fed animals conceived; however, only five were able to carry their infants to term. As was the case with infants of animals given the higher levels of PCB's, all the infants were small and at birth their skin contained detectable levels of PCB's.

The infants were permitted to nurse their mothers for 4 months. Within 2 months focal areas of hyperpigmentation, swollen lips and eyelids, loss of eyelashes, and acneform lesions of the face developed. The skin of these infants showed a decided increase in the PCB level over this period. Within 4 months, 3 of the 6 infants died due to PCB intoxication. After weaning, the

remaining three have shown improvement of the skin lesions during the 4-month period.

Four adult male rhesus monkeys were also exposed to a diet containing 5.0 ppm PCB's (Aroclor 1248) (table 1) for 17 months (average total intake of PCB's 460 mg). They began to develop a slight periorbital edema after 8 months of exposure; however, it was much less severe than in the female monkeys receiving a similar level of PCB. The morphological features and viability of the spermatozoa as well as the ability to fertilize control female rhesus monkeys was unaffected during the initial 12 months of PCB exposure. Subsequently one of the four males lost weight and developed alopecia, acne, periorbital edema and decreased libido. A testicular biopsy of this animal showed a decided hypoactivity of the seminiferous tubules. There was an absence of mature spermatozoa and a predominance of Sertoli cells of the tubules. The remaining three males have remained healthy and sexually active (ref. 15).

ABSORPTION, METABOLISM, TISSUE DEPOSITION, AND EXCRETION OF PCB's

Over 90 percent of a single oral dose (1.5 or 3.0 g per kg) of PCB's (Aroclor 1248) given to adult rhesus monkeys was absorbed from the gastrointestinal tract. Chromatographic analysis of the tissues 14 days after exposure revealed a predominance of higher chlorine isomers that had a predilection for the adipose tissue and organs containing a high fat content (ref. 16).

Rhesus monkeys fed 25 ppm PCB (Aroclor 1248) in the diet attained levels of 127 $\mu\text{g/g}$ within the adipose tissue after 2 months. Eight months after discontinuation of exposure to PCB's the levels were 34 $\mu\text{g/g}$ within the adipose tissue. After 33 months, the levels within the adipose tissue ranged from 3 to 14 $\mu\text{g/g}$; the residues contained greatly increased proportions of highly chlorinated congeners. Transplacental movement of the PCB's was demonstrated by the presence of PCB's in the infants born to exposed females. The tissues of an infant, born to a female 8 months following the discontinuation of PCB's in the diet, contained 25 $\mu\text{g/g}$ of PCB in the fat and adrenal tissues at the time of birth. In an infant born to a female 29 months following the discontinuation of PCB's, the levels within the adipose tissue were 3.38 $\mu\text{g/g}$ at 4 months of age.

Female monkeys given 5.0 ppm PCB in their diets attained maximum levels of PCB's within their adipose tissue at 8 months (141 to 177 $\mu\text{g/g}$ adipose tissue). However, it required approximately 14 months on the 2.5 ppm diet for the monkeys to reach similar maximum PCB levels in their adipose tissue (126 to 144 $\mu\text{g/g}$). Males which received 5.0 ppm PCB's attained levels

Table 1. Experiments on exposure of primates to PCB's (Aroclor 1248*)

Level of PCB in diet (ppm)	No. of animals	Length of exposure (months)	Total PCB intake
300	6 males	3	3.6 to 5.4 g
100	6 males	2	0.8 to 1.0 g
25	6 females	2	250 to 400 mg
2.5	8 females	16-19	243 to 303 mg
5.0	8 females	16-19	460 to 614 mg
5.0	4 males	17	530 to 692 mg

*Monsanto Co., Inc., St. Louis, Missouri.

Table 2. Modification in reproduction
in primates that were exposed
to Aroclor 1248 in the diet

	Control	2.5 ppm	5.0 ppm
Total impregnated (no./no. animals)	12/12	8/8	6/8
Resorptions or abor- tions (no./ no. animals)	0/12	3/8	4/8
Stillborn (no./no. animals)	0/12	0/8	1/8
Normal births (no./ no. animals)	12/12	5/8	1/8

ranging from 128 to 200 μg per g adipose tissue at 14 months. Infants born of mothers exposed to 2.5 and 5.0 ppm PCB's within the diet contained concentrations of PCB's ranging from 1.0 to 4.8 $\mu\text{g/g}$ within the skin at birth. While nursing from mothers consuming PCB diets, the infants continued to accumulate the compound. At 3 months, the levels within the tissues ranged from 86 to 136 $\mu\text{g/g}$. The concentration of PCB's within the milk ranged from 0.15 to 0.40 $\mu\text{g/g}$. The tissues of the infants which died while nursing PCB-fed mothers contained high levels of PCB's within the thymus, ovaries, brain, kidneys, adrenal glands and pancreas (20-48 $\mu\text{g/g}$ tissue). Lower levels were found in the liver, lymph nodes, and bone marrow (8-16 $\mu\text{g/g}$).

Monkeys and rats demonstrate species variation in the metabolic response to the PCB congener 2,5,2',5'-tetrachlorobiphenyl (TCB). Over 68 percent of the single dose (500 mg/kg) administered to rats was recovered from the feces, and an additional 10 percent was present in the urine within the initial 72 hours (ref. 17). The material present in the body was concentrated within the adipose tissue. There was a transient high level of TCB within the blood at 24 hours. Other organs which contained significant quantities of TCB, however at lower concentrations, included the liver, skin, and muscle. The major urinary metabolite was identified as 3-OH-2,5,2',5'-tetrachlorobiphenyl. Other monohydroxy TCB metabolites were present in minor quantities (ref. 17).

Over 90 percent of an oral dose (500 mg/kg) of ^3H TCB administered to infant rhesus monkeys was absorbed from the gastrointestinal tract and was highly concentrated in the skin, adrenal gland, liver, and adipose tissue. At 72 hours, less than 2 percent of the dose had been eliminated in the urine and 1 percent in the feces. Monohydroxy TCB, a major metabolite present in the rat urine, was a minor metabolite in the urine of the monkeys. The two major metabolites were dihydroxy-TCB and trans-3,4-dihydro-3,4-dihydroxy TCB (ref. 18). A second minor metabolite was hydroxy-3,4-dihydro-3,4-dihydroxy TCB.

Following the oral dose of ^3H -TCB (1 g/kg) to juvenile monkeys, a major percentage of the material was absorbed from the gastrointestinal tract and was highly concentrated in the adrenal, adipose tissue, and skin. Significant quantities were present within the liver, muscle, and uterus. After 4 weeks, 14.8 percent of the dose was secreted into the bile. Approximately 75 percent of the biliary material was reabsorbed by the gut and the nonabsorbed material was recovered from the feces during this period. Over 90 percent of the PCB's excreted in the bile was in the form of water soluble

glucuronic acid conjugates. An additional 8 percent of the total dose was recovered from the urine.

Administration of the higher chlorine congener ^3H 2,4,5,2',4',5'-hexachlorobiphenyl (HCB) to rats or monkeys demonstrated low levels of excretion into the bile. An oral dose of HCB (1 g/kg) administered to rats resulted in excretion of 0.3-0.7 percent of the dose per day in the bile over a period of 14 days. The urine was free of detectable levels of radioactivity (ref. 19). At 14 days, 65 percent was recovered from the body tissues. The compound was highly concentrated within the adrenal glands, adipose tissue, and skin and in the female within the ovaries and uterus. Following the administration of a single dose of HCB (1 g/kg) to juvenile rhesus monkeys, less than 2 percent was excreted via the biliary-fecal route over a 3-week period. There was no detectable radioactivity within the urine. The organs with the highest concentration of the material included the adrenal, adipose tissue, and skin. Due to the large mass of muscular tissue, this was a major reservoir of the compound.

INTERACTION OF METABOLITES WITH CELLULAR MACROMOLECULES

Following the administration of ^3H 2,5,2',5'-tetrachlorobiphenyl (TCB) to infant rhesus monkeys, interaction of TCB and macromolecules of cells and of serum was evaluated (ref. 20). Separation of the serum constituents by polyacrylamide gel electrophoresis demonstrated association of the TCB primarily with serum albumin. Over 90 percent of the radioactivity of liver homogenates eluted from a Sephadex G-25 column was in the protein and nucleic acid fractions. The majority of the macromolecular-associated HCB apparently was bound by hydrophobic association. Extraction of liver homogenates with hexane, precipitation of the hexane-extracted homogenate with TCA, and subsequent extraction of the TCA precipitate with methanol resulted in extraction of the majority of the radioactivity. In the extracted residue, 1.1 percent of the radioactivity remained which may represent covalently bonded material. Recent *in vitro* studies employing monkey microsomes incubated with an NADPH generating system demonstrated 20 percent of the metabolized ^3H -TCB was bound to microsomal protein and RNA in a nonextractable form. Binding of ^3H -TCB was prevented by heating the microsomes to 100°C prior to incubation (ref. 21).

DISCUSSION

These experiments employing nonhuman primates have demonstrated development of parallel signs and

lesions of PCB intoxication in humans and rhesus monkeys exposed to similar levels over comparable periods of time. Acne, subcutaneous edema of the face, and edema of the eyelids were observed in man (ref. 22) and lower primates (ref. 15) exposed to PCB's. The facial signs of PCB exposure appear to be a sensitive indicator of PCB intoxication. The rhesus monkeys after exposure for 2 months to dietary levels of PCB's (2.5 and 5.0 ppm) developed facial alterations after a total consumption of 32-50 mg of PCB's. It is noteworthy that PCB levels of 5.0 ppm are presently permitted in foods destined for human consumption.

The most debilitating lesions in the monkeys were the severe hyperplasia and ulceration of the stomach. Whether similar changes occur in the stomach of man exposed to PCB's remains to be clarified. Nausea and anorexia described by the human subjects suggest potential gastric alterations. Liver hypertrophy, proliferation of the endoplasmic reticulum, and increased hepatic microsomal enzyme activities were observed in man (ref. 23) and in lower primates (ref. 11).

Menstrual irregularities, decreased libido, occurrence of stillbirths, reduced birth weights, and transplacental movement of PCB's in humans and rhesus monkeys have been recorded (refs. 13,24). The reproductive failures of monkeys exposed to PCB's were due to inability to maintain a pregnant state. The majority of the animals did not experience appreciable difficulty in conception; however, a large percentage of the animals aborted during the first 45 days of pregnancy. These observations suggest an inability of implantation or inability to maintain the implanted embryo during the early stages of pregnancy.

Although the mechanism of reproductive dysfunction has not been clarified, there is some indication of hormonal modifications. Alterations in the urinary ketosteroids were reported in humans exposed to PCB's (ref. 22). Increased levels of urinary ketosteroids have been observed in the nonhuman primates that experienced reproductive failures (ref. 14). One mechanism of altered steroid metabolism may be secondary to the increase in the hepatic mixed function oxidases that are present in the hypertrophic livers of exposed animals. It has also been a consistent observation that the organs associated with steroid production, the adrenals and ovaries (particularly the corpora lutea), have contained relatively high concentrations of PCB's in exposed animals. Thus the compounds may possibly have a direct effect on these organs.

The presence of PCB's in the milk of other species has been previously reported (ref. 3). This avenue of infant exposure and the potential morbidity and mortality was vividly demonstrated in the infant monkeys

who nursed from mothers exposed to 2.5 and 5.0 ppm in the maternal diets. The presence of relatively low levels of PCB's in the diets of lactating females represents a potential source of PCB intoxication to nursing infants.

Metabolic studies of the rhesus monkey demonstrate over 90 percent absorption of the PCB's from the gastrointestinal tract following oral administration. The material is concentrated in organs with high lipid content, including the adipose tissue, skin, adrenal, corpora lutea of the ovaries, and brain. Within the liver the greatest portion of the material is associated with the membranes of the endoplasmic reticulum.

Studies with the single congener TCB demonstrate the metabolism of the compound to hydroxylated forms which are conjugated with glucuronic acid and excreted into the bile. Enterohepatic circulation of the PCB's undoubtedly occurs as only 20 percent of the material secreted into the bile was recovered from the feces. The greatest portion of the metabolized TCB was excreted through the urinary system. The more highly chlorinated biphenyl HCB was more slowly eliminated from the body via the biliary-fecal route; HCB or metabolites were not detected within the urine. The facilitated metabolism and excretion of the lower chlorine congeners was also indicated by the relative decreased storage of these compounds, and conversely the accumulation of higher chlorinated congeners, within the adipose tissue.

Metabolic studies that have been conducted on non-human primates suggest mechanisms of interaction of PCB's with tissues and, more importantly, indicate potential mutagenic and carcinogenic effects of the PCB's. Metabolites have been isolated from rhesus monkeys exposed to the PCB congener 2,5,2',5'-tetrachlorobiphenyl that are formed through an arene oxide intermediate (ref. 18). Similar metabolites of the PCB's and the potential for arene oxide formation has been demonstrated in rabbits (refs. 25,26). Arene oxides formed by the metabolism of other aromatic hydrocarbons have been shown to covalently bind with macromolecules and produce mutagenic and carcinogenic changes in mammalian cells (ref. 27). Dechlorination of the more highly chlorinated biphenyls, demonstrated by dechlorination of 2,4,5,2',4',5'-hexachlorobiphenyl (ref. 28), provides a mechanism through which metabolism of highly chlorinated biphenyls through an arene oxide intermediate would be facilitated.

Evidence demonstrating the association of PCB's with liver macromolecules supports the theoretical potential of the PCB's for covalent binding with cellular macromolecules. Thus, it appears that alkylation of macromolecules is one mechanism by which the PCB

metabolites cause widespread injurious effects. Further credence for the ability of the compound to produce alterations in the macromolecules is presented in recent reports of hepatocellular tumors developing in rats and mice exposed to PCB's (refs. 29-31).

REFERENCES

1. S. Jensen, "Report of a New Chemical Hazard," *New Scientist*, Vol. 32 (1968), p. 612.
2. M. Kuratsune, "An Epidemiologic Study on 'Yusho' or Chlorobiphenyls Poisoning," *Fukuoka Acta Medica* Vol. 60 (1969), p. 403.
3. A. C. Kolbye, "Food Exposures to Polychlorinated Biphenyls," *Environ. Health Persp.*, Vol. 1 (1972), pp. 85-88.
4. F. J. Biros, A. C. Walker, and A. Medbery, "Polychlorinated Biphenyls in Human Adipose Tissue," *Bull. Environ. Contam. Toxicol.*, Vol. 5 (1970), pp. 317-323.
5. J. Finklea, L. E. Priester, J. P. Creason, T. Hauser, T. Hinner, and D. I. Hammer, "Polychlorinated Biphenyl Residues in Human Plasma Expose a Major Urban Pollution Problem," *Amer. J. Pub. Health*, Vol. 62 (1972), pp. 645-651.
6. J. R. Allen, L. A. Carstens, and L. J. Abrahamson, "Responses of Rats Exposed to Polychlorinated Biphenyls for Fifty-Two Weeks. I. Comparison of Tissue Levels of PCB and Biological Changes," *Arch. Environ. Contam. Toxicol.*, Vol. 4, in press.
7. M. L. Keplinger, O. E. Fancher, J. C. Calandra, and E. P. Wheeler, "Toxicological Studies with Polychlorinated Biphenyls," paper presented at the NIEHS Polychlorinated Biphenyl Conference, Research Triangle Park, North Carolina, December 20-21, 1971.
8. J. R. Allen and L. J. Abrahamson, "Morphological and Biochemical Changes in the Liver of Rats fed Polychlorinated Biphenyls," *Arch. Environ. Contam. Toxicol.*, Vol. 1 (1973), pp. 266-272.
9. J. R. Allen, L. A. Carstens, and D. H. Norback, "Biological Effects of the Polychlorinated Biphenyls in Nonhuman Primates," paper presented at International Symposium on Recent Advances in the Assessment of the Health Effects of Environmental Pollution, Paris, June 24-28, 1974.
10. J. R. Allen and D. H. Norback, "Polychlorinated Biphenyl and Triphenyl Induced Gastric Mucosal Hyperplasia in Primates," *Science*, Vol. 179 (1973), pp. 498-499.
11. J. R. Allen, L. J. Abrahamson, and D. H. Norback, "Biological Effects of Polychlorinated Biphenyls and Triphenyls on Subhuman Primates," *Environ. Res.*, Vol. 6 (1973), pp. 344-354.
12. J. R. Allen, L. A. Carstens, and D. A. Barsotti, "Residual Effects of Short-Term, Low-Level Exposure of Nonhuman Primates to Polychlorinated Biphenyls," *Toxicol. Appl. Pharmacol.*, Vol. 30 (1974), pp. 440-451.
13. D. A. Barsotti, R. J. Marlar, and J. R. Allen, "Reproductive Dysfunctions in Rhesus Monkeys Exposed to Low Levels of Polychlorinated Biphenyls (Aroclor 1248)," *Food Cosmet. Toxicol.*, in press.
14. D. A. Barsotti and J. R. Allen, "Effects of Polychlorinated Biphenyls on Reproduction in the Primate," *Fed. Proc.*, Vol. 34 (1975), p. 338.
15. J. R. Allen, "Response of Primates to Polychlorinated Biphenyl Exposure," *Fed. Proc.*, Vol. 34 (1975), pp. 1675-1679.
16. J. R. Allen, D. H. Norback, and I. C. Hsu, "Tissue Modifications in Monkeys as Related to Absorption, Distribution and Excretion of Polychlorinated Biphenyls," *Arch. Environ. Contam. Toxicol.*, Vol. 2 (1974), pp. 86-94.
17. J. P. Van Miller, I. C. Hsu, and J. R. Allen, "Distribution and Metabolism of ³H-2,5,2',5'-tetrachlorobiphenyl in Rats," *Proc. Soc. Exp. Biol. Med.*, Vol. 148 (1975), pp. 682-687.
18. I. C. Hsu, J. P. Van Miller, J. L. Seymour, and J. R. Allen, "Urinary Metabolites of 2,5,2',5'-tetrachlorobiphenyl in the Nonhuman Primate," *Proc. Soc. Exp. Biol. Med.*, Vol. 150 (1975), pp. 185-188.
19. D. H. Norback, J. L. Seymour, and J. R. Allen, "Metabolic Study on ³H-2,4,5,2',4',5'-hexachlorobiphenyl and ³H-2,5,2',5'-tetrachlorobiphenyl in Rats," *Amer. J. Path.*, (1976) in press.
20. I. C. Hsu, J. P. Van Miller, and J. R. Allen, "Metabolic Fate of ³H-2,5,2',5'-tetrachlorobiphenyl in Infant Nonhuman Primates," *Bull. Environ. Contam. Toxicol.*, Vol. 14 (1975), pp. 233-240.
21. J. L. Seymour, S. P. Schmidt, and J. R. Allen, "In vitro Generation of a Chemically Reactive Metabolite of 2,5,2',5'-tetrachlorobiphenyl by Rhesus Monkey Liver Microsomes," *Proc. Soc. Exp. Biol. Med.*, submitted.
22. M. Kuratsune, T. Yoshimura, J. Matsuzaka, and A. Yamaguchi, "Epidemiologic Study on Yusho, a Poisoning Caused by Ingestion of Rice Oil Contaminated with a Commercial Brand of Polychlorinated Biphenyls," *Environ. Health Persp.*, Vol. 1 (1972), pp. 119-128.
23. C. Hirayama, T. Iriya, and T. Yamamoto, "Fine Structural Changes of the Liver in a Patient with

- Chlorobiphenyls Intoxication," *Fukuoka Acta Medica*, Vol. 60 (1969), p. 455.
24. M. Kikuchi and M. Hashimoto, "Histopathological Studies of Skin Lesions of Patients With Chlorobiphenyls Poisoning," *Fukuoka Acta Medica*, Vol. 60 (1969), pp. 484-488.
 25. A. M. Gardner, J. R. Chen, J. A. G. Roach, and E. P. Regalis, "Polychlorinated Biphenyls: Hydroxylated Urinary Metabolites of 2,5,2',5'-tetrachlorobiphenyl Identified in Rabbits," *Biochem. Biophys. Res. Comm.*, Vol. 55 (1973), pp. 1377-1384.
 26. S. Safe, O. Hutzinger, and D. Jones, "The Mechanism of Chlorobiphenyl Metabolism," *J. Agric. Food Chem.*, Vol. 23 (1975), pp. 851-853.
 27. D. M. Jerina and J. W. Daly, "Arene Oxides: A New Aspect of Drug Metabolism," *Science*, Vol. 185 (1974), pp. 573-582.
 28. O. Hutzinger, W. D. Jamieson, S. Safe, L. Paulmann, and R. Ammon, "Identification of Metabolic Dechlorination of Highly Chlorinated Biphenyl in Rabbit," *Nature*, Vol. 252 (1974), pp. 698-699.
 29. R. D. Kimbrough, R. A. Squires, R. E. Linder, J. D. Strandberg, R. J. Montali, and V. W. Burse, "Induction of Liver Tumors in Rats by Polychlorinated Biphenyl Aroclor 1260," *J. Nat'l. Cancer Inst.*, in press.
 30. N. Ito, H. Nagasaki, S. Makura, and M. Arai, "Histopathological Studies on Liver Tumorigenesis in Rats Treated with Polychlorinated Biphenyls," *Gann*, Vol. 65 (1974), pp. 545-549.
 31. H. Nagasaki, S. Tomii, T. Mega, M. Marugami, and N. Ito, "Hepatocarcinogenicity of Polychlorinated Biphenyls in Mice," *Gann*, Vol. 63 (1972), p. 805.

DISCUSSION

VOICE: I'm from the Massachusetts Society. Have you examined the samples for minute contaminants?

DR. ALLEN: That is a good question. I presume your primary interests are in the dibenzofurans. The Monsanto Company has volunteered to analyze the Aroclor 1248 used in our experiments for the furans. In our discussion last week they were hopeful of having these data available for this conference. If Dr. Wright is in the audience perhaps he would give us a progress report on the subject. (No answer from the audience.) I can say that we have done some preliminary work in this area and have found undetectable levels of furans in the samples. However, more detailed studies to clarify this question are underway at the present time.

VOICE: How can you determine that the PCB's are covalently bound to macromolecules?

DR. ALLEN: Repeated extractions carefully monitored for radioactivity are the best methods of removing any absorbed material from the protein. Standard gel chromatography methods do not differentiate between adsorption and covalently bound materials. We hope to be able to generate enough PCB bound to macromolecules to permit the determination of the exact covalent nature of the bond following macromolecular digestion.

VOICE: Which macromolecule did you use?

DR. ALLEN: We were using protein and RNA from monkey microsomes. These microsomes were incubated with ³H PCB in a NADPH generating system. The protein and RNA were isolated subsequently and their radioactivity determined.

VOICE: Could you tell us roughly how much PCB your animals consumed per kilogram of body weight?

DR. ALLEN: The female animals on the PCB experiments weighed between 6 and 7 kilograms. Table 1 gives the average total intake of PCB's by these animals during the various experiments.

PCB CHLORINATION VERSUS PCB DISTRIBUTION AND EXCRETION

H. B. Matthews, Ph.D.* and M. Anderson, Ph.D.†

Abstract

The distribution and excretion of selected ¹⁴C-labeled polychlorinated biphenyls (PCB's) were studied in the male rat. The distribution and excretion of each of the PCB's was studied after either i.v. or oral administration. Following administration, each of the PCB's was rapidly removed from the blood and stored in the liver and muscle. The rates of PCB redistribution from liver and muscle to skin and adipose tissue and/or elimination in urine was related to the degree of chlorination. The subsequent rates of PCB removal from skin and adipose tissue, excretion in urine, and total excretion were related to the degree and position of chlorination of the biphenyl molecule. None of the PCB's studied was excreted to a significant extent prior to metabolism to more polar compounds. It appears as if the degree and position of chlorination controls the rate of metabolism. The limiting factor in metabolism may be the facility of arene oxide formation as a metabolic intermediate. The toxicologic implications of arene oxide formation versus PCB accumulation in animal tissues are discussed.

INTRODUCTION

Due to the complexity of commercial polychlorobiphenyl (PCB) formulations and the difficulty faced by others in their efforts to interpret the results of toxicological studies in which these mixtures were used, we have chosen to study selected individual PCB's. We believe that detailed studies of individual PCB's, chosen to represent industrial PCB formulations, may not only afford an insight into the biological fate of the more complex commercial formulations, but may also be used in the construction of pharmacokinetic models of the distribution and excretion of these and other chlorinated hydrocarbons. Our ultimate goal is to have pharmacokinetic models which will permit the accurate extrapolation of animal data to man.

Four of the PCB's studied were 4 chloro-, 4,4'-dichloro-, 2,4,5,2',5'-pentachloro-, and 2,4,5,2',4',5'-hexachlorobiphenyl. These PCB's have degrees of chlorination similar to, and are constituents of Aroclors

1221, 1232, 1254, and 1260, respectively. Each of the PCB's studied was labeled with carbon -14.

METHODS

All of the data presented in this paper were obtained with an i.v. dose of 0.6 mg PCB/kg body weight; however, studies with the pentachlorobiphenyl at doses ranging from 0.06 to 6.0 mg/kg failed to show any effect of dose on the distribution and excretion of this PCB (ref. 1). The results presented in this paper were obtained by i.v. injection of the PCB's; however, these results have been repeated without different results by studies in which the PCB's were administered by oral intubation (ref. 2). In these studies, the time points of sampling ranged from 15 minutes to 7 days for each of the PCB's and up to 42 days for the penta- and hexachlorobiphenyls. Three animals were treated and sacrificed at each time point and the data presented represent the average values obtained. The total radioactivity in the tissue samples was determined by oxidation and liquid scintillation counting.

RESULTS

Following i.v. injection, approximately 90 percent of the total dose of each PCB was removed from the blood within 15 minutes. Initially, most of the administered dose was stored in the liver and muscle. Within 15 minutes after administration, the liver contained 15 to 30 percent of the total dose of each of the PCB's (figure 1). Removal of mono- and dichlorobiphenyl from liver was primarily via excretion in the bile in the form of several metabolites; only trace amounts of the parent compounds were excreted in the bile. The pentachlorobiphenyl was removed from the liver by metabolism and excretion in the bile and by redistribution to other tissues, whereas the primary mechanism for the removal of hexachlorobiphenyl from the liver was redistribution. Due to the relatively large mass of muscle, total storage of the PCB's in muscle was similar to that observed in liver (figure 2). It is assumed that the only mechanism of PCB removal from muscle was by redistribution to tissues having a higher affinity for these compounds (ref. 2).

Most of the long-term storage of PCB's in the body was in the skin and adipose tissue. Since one of the earliest symptoms of chronic intoxication by PCB's and certain other chlorinated hydrocarbons is chloracne, a skin disorder (ref. 3), data on the accumulation of these

*Pharmacology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

†Environmental Biometry Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.




Figure 1. Rate of removal of PCB's from liver.




Figure 2. Rate of removal of PCB's from muscle.

compounds in skin was of particular interest (figure 3). It may not be obvious in figure 3, due to the long time scale of 8 hours to 42 days, but the uptake of PCB's by skin was slower than the uptake by liver and muscle (ref. 2). The rate of PCB removal from skin decreased as the degree of chlorination of the PCB's increased, and following the removal of approximately 25 percent of the hexachlorobiphenyl, little further decay from skin was observed during the remainder of the 42-day study.

The accumulation of PCB's in adipose tissue was a slower process than that observed in skin (figure 4). The peak concentrations of mono-, di-, penta-, and hexachlorobiphenyl in adipose tissue were reached at 1 hour, 2 hours, 4 hours, and 7 days after administration, respectively. The magnitude of the peak concentrations in fat also tended to increase with increasing chlorination, whereas the rates of PCB removal from adipose tissue decreased with increasing chlorination of the PCB. Hexachlorobiphenyl concentrations in fat never showed a decline from peak concentrations.

The rates of PCB removal from tissues would be expected to be reflected in their rates of excretion. All rats kept for 1 day or longer were held in individual metabolism cages and fed food and water *ad libitum*. Both urine and feces were collected daily. The most dramatic effect of increasing chlorination of the biphenyl molecule was seen in the percent of the total dose excreted in the urine (figure 5). Cumulative excretion in urine for 7 days accounted for approximately 60, 34, 8, and less than 1 percent of the total mono-, di-, penta-, and hexachlorobiphenyl dose, respectively. Greater than 90 percent of the material excreted in the urine was in the form of one or more conjugated metabolites of the given PCB (ref. 2).

Cumulative excretion of the PCB's in feces was a more consistent process which, with the exception of the hexachlorobiphenyl, did not appear to be greatly affected by degree of chlorination (figure 6). Animals treated with penta- or hexachlorobiphenyl were held for up to 42 days. Extrapolation of the daily rates of total PCB excretion showed that, with the exception of hexachlorobiphenyl, excretion would eventually account for approximately 100 percent of the administered dose of each PCB. The excretion of hexachlorobiphenyl was so slow that extrapolation to infinite time indicated that less than 20 percent of the administered dose would ever be excreted.

DISCUSSION

Work in our laboratory and elsewhere indicates that only about 10 percent of each of these PCB's is excreted as the parent compound. We also know from extraction

and analysis of the radioactivity in the tissues that appreciable amounts of the metabolites are not stored in the tissues (ref. 2). We have thus assumed that metabolism is a prerequisite to the excretion of PCB's. We have also shown that the rates of excretion and the rates of removal from skin and adipose tissues of mono-, di-, and pentachlorobiphenyl are inversely proportional to their degrees of chlorination (ref. 2). On the other hand, the very slow excretion of hexachlorobiphenyl would not have been predicted by this relationship. Therefore, an additional factor appeared to be affecting the rate of metabolism of hexachlorobiphenyl.

An examination of the molecular structures of these four PCB's shows that there is only one obvious difference, other than chlorination, among the structures of the hexachlorobiphenyl and the three other PCB's. The difference is that this hexachlorobiphenyl does not have two adjacent unsubstituted carbon atoms.

It was demonstrated in Williams' laboratory in the 1950's that chlorinated benzenes that had two adjacent unsubstituted carbon atoms were metabolized and excreted 3 to 20 times more rapidly than benzenes with similar degrees of chlorination that did not have adjacent unsubstituted carbon atoms (refs. 4,5). Schulte and Acker suggested that a similar substitution pattern is required for the metabolism of PCB's (ref. 6). This suggestion was partially confirmed by Jensen and Sundstrom (ref. 7) when they showed that PCB's which did not have two adjacent unsubstituted carbon atoms were found in the highest concentrations in the tissues of higher animals and man. The hexachlorobiphenyl used in our studies was found in the highest concentrations of any PCB in human tissues. Our data on the distribution and excretion of this PCB and the fact this particular PCB is one of the more common constituents of the more highly chlorinated commercial PCB formulations explain why such high concentrations were found in human and animal tissues.

As a point of reference, we have also studied the distribution and excretion of similar doses of several chlorinated pesticides in the rat. The initial half-life of dieldrin was quite similar to that of pentachlorobiphenyl. The initial half-life of DDT was five- to six-fold longer than that of pentachlorobiphenyl and only Mirex and hexachlorobenzene, of the pesticides tested, had infinitely long half-lives such as that observed for hexachlorobiphenyl (ref. 8).

Two adjacent unsubstituted carbon atoms are important to the metabolism of the PCB's because their presence facilitates the formation of arene oxides. Arene oxides are formed by the hepatic mixed-function oxidases as intermediates in the metabolism of a number of lipophilic compounds, and these oxides have been




Figure 3. Rate of removal of PCB's from skin.




Figure 4. Rate of removal of PCB's from adipose tissue.




Figure 5. Cumulative excretion of PCB's in urine.




Figure 6. Cumulative excretion of PCB's in feces.

implicated as potential carcinogens (refs. 9,10). Evidence for arene oxides as intermediates in the metabolism of implicated as potential carcinogens (refs. 9,10). Evidence for arene oxides as intermediates in the metabolism of PCB's has been provided by Gardner et al. (ref. 11), Safe et al. (ref. 12), and in our own laboratory (ref. 13).

Thus, we are given a dilemma. Those PCB's which can be metabolized and excreted may be metabolized via a carcinogenic intermediate and those PCB's which are not readily metabolized have an extremely long biological half-life. Several researchers have provided evidence that the PCB's may be carcinogenic (refs. 14-16). On the other hand, Vos et al. (ref. 17) have shown the very slowly metabolized hexachlorobiphenyl used in this study to be acrogenic, to cause liver damage, and to induce hepatic porphyria. It is not yet known if it is the parent PCB's or their metabolites which account for the primate reproductive failures described by Allen (ref. 18). The only way that we are going to establish which of the PCB's or their metabolites are carcinogenic or are going to cause any of the other toxicological problems and at what levels of exposure the problems are likely to arise is through systematic pharmacokinetic studies, which will allow us to extrapolate the results of chronic low-dose environmental exposures from laboratory animals to man. Until such data are available, it is my opinion that every effort should be made to avoid environmental contamination by any type of PCB's.

REFERENCES

1. H. B. Matthews, and M. W. Anderson, "The Distribution and Excretion of 2,4,5,2',5'-Pentachlorobiphenyl in the Rat," *Drug Metab. Dispos.*, Vol. 3, No. 3 (1975), pp. 211-219.
2. H. B. Matthews, and M. W. Anderson, "Effect of Chlorination on the Distribution and Excretion of Polychlorinated Biphenyls," *Drug Metab. Dispos.*, Vol. 3, No. 5 (1975), pp. 371-380.
3. R. D. Kimbrough, "Toxicity of Chlorinated Hydrocarbons and Related Compounds," *Arch. Environ. Health*, Vol. 25 (1972), pp. 125-131.
4. W. R. Jondorf, D. V. Parke, and R. T. Williams, "Studies in Detoxication, 66. The Metabolism of Halogenobenzenes, 1:2:3-, 1:2:4- and 1:3:5-Trichlorobenzenes," *Biochem. J.* Vol. 61 (1955), pp. 512-521.
5. W. R. Jondorf, D. V. Parke, and R. T. Williams, "Studies in Detoxication, 78. The Metabolism of Halogenobenzenes, 1:2:3:4-, 1:2:3:5- and 1:2:4:5-Tetrachlorobenzenes," *Biochem. J.*, Vol. 69 (1958), pp. 181-189.
6. E. Schulte, and L. Acker, "Identifizierung und Metabolisierbarkeit von polychlorierten Biphenylen," *Naturwissenschaften*, Vol. 61, No. 2 (1974), pp. 79-80.
7. S. Jensen, and G. Sundstrom, "Structures and Levels of Most Chlorobiphenyls in Two Technical PCB Products and in Human Adipose Tissue," *Ambio*, Vol. 3 (1974), pp. 70-76.
8. H. B. Matthews, unpublished.
9. J. W. Daly, D. M. Jerina, and B. Witkop, "Arene Oxides and the NIH Shift: The Metabolism, Toxicity and Carcinogenicity of Aromatic Compounds," *Experientia*, Vol. 28 (1974), pp. 573-582.
10. D. M. Jerina, and J. W. Daly, "Arene Oxides: A New Aspect of Drug Metabolism," *Science*, Vol. 185 (1974), pp. 573-582.
11. A. M. Gardner, J. T. Chen, J. A. G. Rouch, and E. P. Ragelis, "Polychlorinated Biphenyls: Hydroxylated Urinary Metabolites of 2,5,2',5'-Tetrachlorobiphenyl Identified in Rabbits," *Biochem. Biophys. Res. Comm.*, Vol. 55, No. 4 (1973), pp. 1377-1384.
12. S. Safe, O. Hutzinger, and D. Jones, "The Mechanism of Chlorobiphenyl Metabolism," *J. Agric. Food Chem.* Vol. 23, No. 5 (1975), pp. 851-853.
13. P. R. Chen, J. D. McKinney, and H. B. Matthews, "2,4,5,2',5'-Pentachlorobiphenyl Metabolism in the Rat: Qualitative and Quantitative Aspects," in press.
14. N. Ito, H. Nagasaki, M. Arai, S. Makiura, S. Sugihara, and K. Hirao, "Histopathologic Studies on Liver Tumorigenesis Induced in Mice by Technical Polychlorinated Biphenyls and Its Promoting Effect on Tumors Induced by Benzene Hexachloride," *J. Natl. Cancer Inst.* Vol. 51, No. 5 (1973), pp. 1637-1642.
15. R. D. Kimbrough, and R. E. Linder, "Induction of Adenofibrosis and Hepatomas of the Liver in BALB/cJ Mice by Polychlorinated Biphenyls (Aroclor 1254)," *J. Natl. Cancer Inst.*, Vol. 53, No. 2 (1974), pp. 547-549.
16. R. D. Kimbrough, R. A. Squire, R. E. Linder, J. D. Strandberg, R. J. Montali, and V. W. Burse, "Induction of Liver Tumors in Sherman Strain Female Rats by Polychlorinated Biphenyl Aroclor 1260," *J. Natl. Cancer Inst.*, in press.
17. J. G. Vos, and E. Notenboom-Ram, "Comparative Toxicity Study of 2,4,5,2',4',5'-Hexachlorobiphenyl and a Polychlorinated Biphenyl Mixture in Rabbits," *Toxicol. Appl. Pharmacol.*, Vol. 23 (1972), pp. 563-578.
18. D. A. Barsotti, R. J. Merlar, and J. R. Allen, "Reproductive Disfunctions in Rhesus Monkeys Exposed to Low Levels of Polychlorinated Biphenyls (Aroclor 1248), in press.

ENZYMATIC AND OTHER BIOCHEMICAL RESPONSES TO SELECTED PCB's

D. J. Ecobichon, Ph.D.*

Abstract

Isomerically-pure mono-, di-, tri-, tetra-, hexa-, and octa-chlorobiphenyls were injected i.p. into weanling male rats at a dosage of 50 mg/kg/day for 3 consecutive days, the animals being killed 96 hr after the last injection. The influence of position and degree of chlorination of the biphenyl nucleus on hepatic function was compared to that produced by purified biphenyl. Hepatic function was assessed by pentobarbital sleeping times and in vitro assays of p-nitroanisole O-demethylase, aniline hydroxylase, aminopyrine N-demethylase, carboxylesterase and sulfobromophthalein-glutathione conjugating enzyme activities. For the mono-oxygenases closely associated with the hepatic endoplasmic reticulum, enhanced induction of activity was observed with highly chlorinated biphenyls and by low chlorine-containing congeners having chlorine atoms substituted at the 4- and 4'-positions irrespective of chlorination at other positions. For those enzymes less discretely localized in the hepatocyte, the position of the chlorine atoms appeared to be less important. Interrelationships with other hepatic functions and the rate of chlorobiphenyl biotransformation is discussed.

Toxicologic assessment of commercial chlorobiphenyl mixtures has been complicated by the heterogeneity of the congeners, by marked differences in physical and chemical properties which, undoubtedly, influence rates of absorption, distribution, metabolism and excretion and by the possible presence of toxic impurities and byproducts (refs. 1-4). As techniques of definitive analysis have developed, the complexity of commercial chlorobiphenyls (Aroclors, Monsanto Industrial Chemicals, St. Louis, Mo.) has been revealed showing that, with the exception of Aroclor 1016 and 1232, one predominant congener composed of a number of positional isomers is found in each preparation (fig. 1). As the percentage of chlorine increases, the predominant congener shifts from a mono- to a tri- to a tetra- to a penta-chlorobiphenyl (refs. 5,6).

If it was possible to separate these complex mixtures, one could examine several facets of the toxicology of these compounds, and several questions could be posed and, perhaps, answered. Do the various congeners

possess the same toxicological properties; i.e., do dichlorobiphenyls have the same effect as hexachlorobiphenyls? Do all of the tetrachlorobiphenyl isomers produce the same toxicologic responses? Are the pathologic and toxicologic alterations observed due to the biphenyl nucleus itself, to the positions occupied by individual chlorine atoms, or to the number of chlorines present on the biphenyl nucleus. Since hepatic enzyme induction has been a well-characterized phenomenon of adaptation to these chemicals, we attempted to answer some of the above questions using changes in hepatic ultrastructure and in enzyme activity as indices of structure-activity relationships.

Our first study, completed in 1972, and published in 1974, used a small series of isomerically-pure chlorobiphenyls of known position and degree of chlorination, synthesized and purified by my colleagues, Dr. O. Hutzinger and Dr. S. Safe (refs. 3,7). The objective of these experiments was to elicit responses (induction of hepatic drug-metabolizing enzymes) which, hopefully, could be related to the structures of the pure chlorobiphenyls. We injected young male Wistar strain rats intraperitoneally with 50 mg/kg of the agent, dissolved in peanut oil, for 3 consecutive days, the animals being killed 96 hr after the last injection. The livers were quickly removed and samples were taken and stained for light and electron microscopy. The remaining hepatic tissue was used for the preparation of microsomes and soluble supernatant for the enzymatic assays. These assays included representative functions of the microsomal mono-oxygenases (p-nitroanisole O-demethylase, aniline hydroxylase, aminopyrine N-demethylase), hydrolases (nonspecific carboxylesterase) and the conjugation of sulfobromophthalein (BSP) with reduced glutathione (GSH). Some of the results of that study are shown in the next few figures.

Figure 2 presents the results observed for the cytoplasmic enzyme system involved in conjugating BSP following exposure to DDT, Aroclor 1254 and 1280, biphenyl, and a series of pure chlorobiphenyls. Significant ($p < 0.05$) increases in activity were observed with all agents tested. It should be noted that biphenyl caused a marked increase in this enzyme activity.

Figure 3 shows the influence of the DDT isomers, commercial Aroclors, biphenyl, and the series of isomerically pure chlorobiphenyls on pentobarbital-induced sleeping time. Highly significant ($p < 0.05$) reductions in sleeping time were observed with the

*Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

commercial Aroclors and DDT isomers. Biphenyl and 4-chlorobiphenyl caused no significant ($p > 0.05$) changes in sleeping time. Of the dichloro-isomers, only the 4,4'-isomer significantly reduced the duration of effect. Both tetrachloro-isomers caused significant reductions in sleeping time though the 2,5,2',5'-isomer was less effective. The hexa- and octa-chlorobiphenyls caused a marked reduction in sleeping times, being comparable to those observed with p,p'-DDT and the commercial Aroclors.

Figure 4 summarizes the influence of the various agents tested on the hepatic mixed function oxidases aniline hydroxylase (A), p-nitroanisole O-demethylase (B), and aminopyrine N-demethylase (C). As has been observed by others, we found that the most responsive enzymes were those closely associated with the smooth endoplasmic reticulum. The results in vitro reflected the observations of altered sleeping times in vivo. One can see that, even with this limited number of pure chlorobiphenyls, not all caused effects of the same magnitude. To summarize the results of this study, treatment with biphenyl caused slight induction while 4-chlorobiphenyl did not. The mixed function oxidases were markedly induced by pure hexa- and octa-chlorobiphenyls and also by di- and tetra-chlorobiphenyls with chlorines substituted at the 4-positions of the rings. Considering the dichloro-isomers, when the 4- and 4'-positions were occupied, there was a much greater inductive effect for all of the enzyme activities than was observed with the 2,2'- and 2,4'-isomers. The same positional phenomenon was observed for the two tetra-chlorobiphenyls studied, the induction caused by 2,4,2',4'-tetra-chlorobiphenyl being much greater than that observed with the 2,5,2',5'-isomer. The results obtained for the higher chlorinated analogs suggested that the positions of the chlorine atoms were not as important. Our results, with the exception of the marked effects obtained following treatment with 4,4'-dichlorobiphenyl, confirmed the observations of other investigators who have found that penta-, hexa- and octa-chlorobiphenyls had greater enzyme-inducing potential than did low chlorine-containing biphenyls (refs. 8-11).

On the basis of our initial studies, we came to the conclusion that the biphenyl nucleus could exert some effect on hepatic enzyme levels (fig. 4) though the only function markedly affected was the BSP-GSH conjugation (fig. 2). Much more important conclusions were that not all congeners possessed the same toxicologic properties and that, while greater inductive effects were observed with highly chlorinated biphenyls, marked ultrastructural and enzymatic changes were observed

with specific di- and tetra-chlorobiphenyls, particularly those with chlorines substituted on the 4-position on the ring. We have extended the investigation to a broader series of mono-, di-, tri-, and tetra-chlorobiphenyls in an attempt to confirm the importance of position of the chlorine on the ring structure of low chlorine-containing congeners. Isomerically-pure chlorobiphenyls, synthesized by my colleagues or purchased from Analabs Inc. (North Haven, Conn.), were injected intraperitoneally using the same regimen (50 mg/kg/day for 3 consecutive days, killing the animals 96 hr. after the third injection). A 12,000 g-20 min supernatant from 20% w/v homogenates of liver was used as the enzyme source. This study has been published recently (ref. 12). Some of the pertinent results are shown in the next figures.

It was essential, before studying the effects of chlorination and position, to determine what effects the biphenyl nucleus had on hepatic enzymes. Table 1 shows the results of the i.p. administration of vehicle (peanut oil), commercially available biphenyl (Eastman Organic Chemicals, Rochester, N.Y.), and purified biphenyl on the activities of hepatic O-demethylase (OD), aniline hydroxylase (AH), carboxylesterase (CE), and the BSP-GSH conjugating enzymes. Treatment with unpurified biphenyl resulted in significant ($p < 0.05$) increases in activities of three of the enzymes. In contrast, biphenyl repurified by thin layer chromatography caused a significant increase only in BSP-GSH conjugating enzyme activity, suggesting the presence of an impurity in the commercial material. Since relatively pure chlorobiphenyls were to be used, repurified biphenyl was used for the control groups of animals.

The influence of monochlorobiphenyls on hepatic O-demethylase, aniline hydroxylase, carboxylesterase, and BSP-GSH conjugating enzyme activities are compared in table 2 with the effects following treatment with biphenyl. While changes in microsomal O-demethylase were not observed, all three monochloro-isomers significantly increased aniline hydroxylase and carboxylesterase levels. The BSP-GSH conjugating enzyme activity was not affected.

The influence of a series of di-, tri-, and tetrachlorobiphenyls on the selected enzymatic functions are shown in figures 5, 6, and 7, respectively. With each series of isomers, a chlorine atom on the 4-position caused a more marked induction of hepatic drug-metabolizing enzyme activities than did a chlorine atom at any other position. As one increased the degree of chlorination, subsequent substitution at the 2-position was next in importance followed by substitution at the 3-position. The results conclusively demonstrated that not all isomers of the mono-, di-, tri-, and tetrachloro-

Table 1. The effects of intraperitoneally administered peanut oil, commercial biphenyl, and purified biphenyl dissolved in peanut oil on enzyme activities of rat liver^a

Enzyme	Activities (in total wt of fresh liver/100 g body wt) ^b		
	Vehicle	Commercial biphenyl	Purified biphenyl
p-Nitroanisole O-demethylase	168.0±23.9	211.5±38.7	195.6±19.1
Aniline hydroxylase	102.7±26.7	352.8±102.8 ^c	97.3±15.1
Carboxylesterase	234.4±53.5	336.7±55.3 ^c	236.2±24.7
BSP-GSH conjugating enzyme	5.0± 0.9	14.4± 1.9 ^c	8.8± 0.9 ^c

^aThe animals received 50 mg of biphenyl/kg (0.15-0.25 ml of solution) for 3 consecutive days and were killed 96 hr after the last injection. Vehicle-treated animals received peanut oil on the same volume basis. Twelve animals were treated with vehicle, 11 with commercial biphenyl, and 18 with purified biphenyl.

^bThe activities of O-demethylase and aniline hydroxylase are expressed as nanomoles of product formed/minute. Carboxylesterase activity is expressed as micromoles of substrate hydrolyzed/minute while the BSP-GSH conjugating enzyme activity is expressed as micrograms of conjugate formed/minute. Activities are presented in terms of the total liver/100 g of body wt.

^cValues are statistically different from vehicle-treated control values at p<0.05.

Table 2. Effects of acute intraperitoneal administration of biphenyl and monochlorobiphenyls on hepatic enzyme activity

Treatment	n	Activities (in total wt of fresh liver/100 g body wt) ^a			
		OD ^c (nmol/min)	AH (nmol/min)	CE (μmol/min)	BSP (μg/min)
Biphenyl	18	195.6±19.1	97.3±15.7	236.2±24.7	8.8±0.9
2-Chlorobiphenyl	6	184.8±17.2	188.3±30.4 ^b	309.2±35.1 ^b	7.5±1.5
3-Chlorobiphenyl	6	193.6±28.1	225.8±55.3 ^b	381.7±64.3 ^b	9.8±1.5
4-Chlorobiphenyl	6	233.4±32.5	168.1±37.4 ^b	306.2±24.5 ^b	9.8±1.6

^aValues presented are the mean ± SD of the number of animals per group.

^bValues are significantly different from values obtained from biphenyl-treated animals, p<0.05.

^cThe enzymes investigated include p-nitroanisole O-demethylase (OD), aniline hydroxylase (AH), carboxylesterase (CE), and sulfobromophthaloin-glutathione conjugating enzyme (BSP).




Figure 1. The congener composition of commercially available Aroclors based on the weight percent of biphenyls bearing different numbers of chlorine atoms/molecule. Data were obtained from reports by Webb and McCall (ref. 6), Sissons and Welti (ref. 5), and from information supplied by the Monsanto Industrial Chemicals Company.




Figure 2. The effect of pretreatment of young male rats with DDT (o,p' and p,p'-isomers), Aroclors 1254 and 1260, biphenyl, and a series of isomerically pure chlorobiphenyls on the hepatic cytoplasmic enzyme which conjugates sulfobromophthalein (BSP) with reduced glutathione. Activities are expressed as μg of conjugate formed mg^{-1} protein min^{-1} . Animals were treated by i.p. injection for 3 consecutive days, enzyme activity being determined 96 hr after the last injection. The values (bars) represent mean activities $\pm$ S.D. of the means of 19 control animals and 7 animals per treated group.




Figure 3. The effect of pretreatment of young male rats with DDT (o,p' and p,p'-isomers), Aroclor 1254 and 1260, biphenyl, and a series of isomerically pure chlorobiphenyls on the sleeping time produced by an injection of 40 mg/kg sodium pentobarbital. For other details, see figure 2.




Figure 4. The effect of pretreatment of young male rats with DDT (o,p'- and p,p'-isomers), Aroclor 1254 and 1260, biphenyl, and a series of isomerically pure chlorobiphenyls on hepatic microsomal aniline hydroxylase (A), p-nitroanisole O-demethylase (B), and aminopyrine N-demethylase (C), activities. Activities are expressed as nmoles of product formed/mg microsomal protein/30min incubation. For other details, see figure 2.




Figure 5. The effect of pretreatment of young male rats with biphenyl and series of isomerically pure dichlorobiphenyls on hepatic p-nitroanisole O-demethylase (OD), aniline hydroxylase (AH), carboxylesterase (CE), and sulfobromophthalein-glutathione conjugating enzyme (BSP) activities. Animals were treated by i.p. injection for 3 consecutive days and were killed and assayed 96 hr after the last injection. The values (bars) represent the mean enzymatic activities $\pm$ S.D. (lines) of 18 control, biphenyl-treated rats and 6 animals per treated group. The asterisk (*) indicates values statistically different ($p < 0.05$) from biphenyl-treated controls.




Figure 6. The effects of pretreatment of young male rats with biphenyl and a series of isomerically pure trichlorobiphenyls on hepatic p-nitroanisole O-demethylase (OD), aniline hydroxylase (AH), carboxylesterase (CE), and sulfobromophthalein-gluthathione conjugating enzyme (BSP) activities. For other details, see figure 5.




Figure 7. The effects of pretreatment of young male rats with biphenyl and a series of isomerically pure tetrachlorobiphenyls on hepatic p-nitroanisole O-demethylase (OD), aniline hydroxylase (AH), carboxylesterase (CE), and sulfobromophthalein-gluthathione conjugating enzyme (BSP) activities. For other details, see figure 5.

biphenyls possess the same toxicologic properties, the position of chlorination being as important as degree of chlorination.

The porphyrinogenic nature of chlorinated biphenyls is well known (refs. 2,13-15). Goldstein et al. and Grote et al. demonstrated marked increases in δ -aminolevulinic acid synthetase following treatment with commercial chlorobiphenyls (refs. 15,16). This enzyme, located in hepatic mitochondria, is the rate-limiting catalyst in the synthesis of heme and prophyryns. Recently, Goldstein et al. completed a study of the effects on chick liver, feeding five different, isomerically pure hexachlorobiphenyls at concentrations of 400 ppm or 3 weeks (ref. 17). All agents caused uroporphyrin accumulation, increased hepatic cytochrome P-450, and microsomal drug-metabolizing enzymes but only 3,4,5,3',4',5', 2,3,4,2',3',4', and 2,4,5,2',4',5'-hexachlorobiphenyl caused gross accumulation of hepatic porphyrins. These isomers were also the most toxic. It is notable that these three isomers had both the *m*- and *p*-positions occupied by chlorines, while the other two isomers (2,3,6,2',3',6' and 2,4,6,2',4',6') had either the *m*- or the *p*-positions unoccupied.

Several investigators have demonstrated that the low chlorine-containing congeners in commercial mixtures disappeared more rapidly from tissues than did the highly chlorinated biphenyls (refs. 18-22). In our earliest paper, we suggested that the magnitude of hepatic enzyme induction might be related to the rate of degradation and elimination of the congeners from the body (3). There is ample evidence of hydroxylated derivatives of chlorobiphenyls being eliminated from mammalian systems and, no doubt, we shall hear more about them at this meeting (refs. 23-27). Evidence in the literature suggests two possible mechanisms of biotransformation. The first and most rapid mechanism involves the formation of an arene oxide intermediate and requires the presence of unsubstituted adjacent (vicinal) carbon atoms in the nucleus (ref. 24,27,28). The second and much slower mechanism uses a different hydroxylating system for isolated unsubstituted positions as are found in highly chlorinated biphenyls (ref. 28). The position of chlorination in low chlorine-containing biphenyls could have considerable directing influence over the pathway of biotransformation. Certain low chlorine biphenyls would be less effective (and less toxic) due to rapid biotransformation via arene oxide intermediates. Others, substituted at a position (i.e., 4-position) which would disrupt the vicinal carbon arrangement, would be unable to undergo rapid biotransformation and would persist in vivo. The toxicity of these agents may be closely correlated with

lipid solubility, high concentration in the liver, and along duration of action, but it is evident that the position of the substituent chlorines on the biphenyl nucleus may be the key factor governing these other properties.

REFERENCES

1. V. Zitko and P. M. K. Choi, "PCB and Other Industrial Halogenated Hydrocarbons in the Environment," Fisheries Research Board of Canada, Technical Report 272, 1971.
2. J. G. Vos and J. H. Koeman, "Comparative Toxicologic Study With Polychlorinated Biphenyls in Chickens With Special Reference to Porphyrin, Edema Formation Liver Necrosis and Tissue Residues," *Toxicol. Appl. Pharmacol.*, Vol. 17 (1970), pp. 656-668.
3. G. J. Johnstone, D. J. Ecobichon, and O. Hutzinger, "The Influence of Pure Polychlorinated Biphenyl Compounds on Hepatic Function in the Rat," *Toxicol. Appl. Pharmacol.*, Vol. 28 (1974), pp. 66-81.
4. O. Hutzinger, S. Safe, and V. Zitko, "The Chemistry of PCB's," CRC Press Inc., 1975.
5. D. Sissons and D. Welti, "Structural Identification of Polychlorinated Biphenyls in Commercial Mixtures by Gas-liquid Chromatography, Nuclear Magnetic Resonance, and Mass Spectrometry," *J. Chromatog.*, Vol. 60 (1971), pp. 15-32.
6. R. G. Webb and A. C. McCall, "Identities of Polychlorinated Biphenyl Isomers in Aroclors," *J. Assoc. Offic. Anal. Chem.*, Vol. 55 (1972), pp. 748-752.
7. M. M. Hansell and D. J. Ecobichon, "Effects of Chemically Pure Chlorobiphenyls on the Morphology of Rat Liver," *Toxicol. Appl. Pharmacol.*, Vol. 28 (1974), pp. 418-427.
8. S. Fujita, H. Tsuji, K. Kato, S. Saeki, and H. Tsukamoto, "Effect of Biphenyl Chlorides on Rat Liver Microsomes," *Fukuoka Acta Med.*, Vol. 62 (1971), pp. 30-34.
9. D. R. Bickers, L. C. Harber, A. Kappas, and A. P. Alvarez, "Polychlorinated Biphenyls: Comparative Effects of High and Low Chlorine-Containing Aroclors on Hepatic Mixed Function Oxidase," *Res. Commun. Chem. Pathol. Pharmacol.*, Vol. 3 (1972), pp. 505-512.
10. P. R. Chen, H. M. Mehendale, and L. Fishbein, "Effect of Two Isomeric Tetrachlorobiphenyls on Rats and Their Hepatic Enzymes," *Arch. Environ. Contam. Toxicol.*, Vol. 1 (1973), pp. 38-47.
11. J. G. Vos and E. Notenboom-Ram, "Comparative Toxicity Study of 2,4,5,2',4',5'-hexachlorobiphenyl

- and a Polychlorinated Biphenyl Mixture in Rabbits," *Toxicol. Appl. Pharmacol.*, Vol. 23 (1972), pp. 563-578.
12. D. J. Ecobichon and A. M. Comeau, "Isomerically Pure Chlorobiphenyl Congeners and Hepatic Function in the Rat: Influence of Position and Degree of Chlorination," *Toxicol. Appl. Pharmacol.*, Vol. 33 (1975), pp. 94-102.
 13. J. G. Vos, J. J. T. W. A. Strik, C. W. M. van Hosteyn, and J. H. Pennings, "Polychlorinated Biphenyls as Inducers of Hepatic Porphyrin in Japanese Quail With Special Reference to δ -amino Levulinic Acid Synthetase Activity, Fluorescence, and Residues in the Liver," *Toxicol. Appl. Pharmacol.*, Vol. 20 (1971), pp. 232-240.
 14. J. A. Goldstein, P. Hickman, and D. L. Jue, "Experimental Hepatic Porphyrin Induced by Polychlorinated Biphenyls," *Toxicol. Appl. Pharmacol.*, Vol. 27 (1974), pp. 437-448.
 15. J. A. Goldstein, P. Hickman, V. W. Burse, and H. Bergman, "A Comparative Study of Two Polychlorinated Biphenyl Mixtures (Aroclor 1242 and 1016) Containing 42% Chlorine on Induction of Hepatic Porphyrin and Drug Metabolizing Enzymes," *Toxicol. Appl. Pharmacol.*, Vol. 32 (1975), pp. 461-473.
 16. W. Grote, A. Schmoldt, and H. F. Bente, "Hepatic Porphyrin Synthesis in Rats After Pretreatment With Polychlorinated Biphenyls (PCB's)," *Acta Pharmacol. et Toxicol.* Vol. 36 (1975), pp. 215-224.
 17. J. A. Goldstein, J. D. McKinney, G. W. Lucier, P. Hickman, H. Bergman, and J. A. Moore, "Toxicology of Hexachlorobiphenyl Isomers and 2,3,7,8-tetrachlorodibenzofuran in Chicks II. Effects on Drug Metabolism and Porphyrin Accumulation," *Toxicol. Appl. Pharmacol.*, accepted for publication, 1975.
 18. J. H. Koeman, M. C. Ten Noever de Brauw, and R. H. de Vos, "Chlorinated Biphenyls in Fish, Mussels and Birds from the River Rhine and the Netherlands Coastal Area," *Nature* (London), Vol. 221 (1969), pp. 1126-1128.
 19. D. L. Grant, W. E. J. Phillips, and D. C. Villeneuve, "Metabolism of a Polychlorinated Biphenyl (Aroclor 1254) Mixture in the Rat," *Bull. Environ. Contam. Toxicol.*, Vol. 6 (1971), pp. 102-112.
 20. S. Bailey and P. J. Bunyan, "Interpretation of Persistence and Effects of Polychlorinated Biphenyls in Birds," *Nature* (London), Vol. 236 (1972), pp. 34-38.
 21. V. W. Burne, R. D. Kimbrough, E. C. Villanueva, R. W. Jennings, R. E. Linder, and G. W. Sovocool, "Polychlorinated Biphenyls, Storage Distribution, Excretion and Recovery: Liver Morphology After Prolonged Dietary Ingestion," *Arch. Environ. Health*, Vol. 29 (1974), pp. 301-307.
 22. A. S. De Freitas and R. J. Norstrom, "Turnover and Metabolism of Polychlorinated Biphenyls in Relation to Their Chemical Structure and the Movement of Lipids in the Pigeon," *Can. J. Physiol. Pharmacol.*, Vol. 52 (1974), pp. 1080-1094.
 23. O. Hutzinger, D. M. Nash, S. Safe, A. W. W. De Freitas, R. J. Norstrom, D. J. Wildfish, and V. Zitko, "Polychlorinated Biphenyls: Metabolic Behavior of Pure Isomers in Pigeons, Rats, and Brook Trout," *Science*, Vol. 175 (1972), pp. 312-314.
 24. A. M. Gardner, J. T. Chen, J. A. G. Roach, and E. P. Regalis, "Polychlorinated Biphenyls: Hydroxylated Urinary Metabolites of 2,5,2',5'-tetrachlorobiphenyl Identified in Rabbits," *Biochem. Biophys. Res. Commun.*, Vol. 55 (1973), pp. 1377-1384.
 25. S. Safe, O. Hutzinger, and D. J. Ecobichon, "Identification of 4-chloro-4'-hydroxy biphenyl and 4,4'-di-chloro-3-hydroxybiphenyl as Metabolites of 4-chloro- and 4,4'-dichlorobiphenyl Fed to Rats," *Experientia*, Vol. 30 (1974), pp. 720-721.
 26. S. Jensen and G. Sundstrom, "Metabolic Hydroxylation of a Chlorobiphenyl Containing Only Isolated Unsubstituted Positions - 2,2',4,4',5,5'-hexachlorobiphenyl," *Nature* (London), Vol. 251 (1974), pp. 219-220.
 27. W. Greb, W. Klein, F. Coulston, L. Golberg, and F. Korte, "Beiträge zur Ökologischen Chemie LXXXIII. In Vitro Metabolism of Polychlorinated Biphenyls - 14 C," *Bull. Environ. Contam. Toxicol.*, Vol. 13 (1975), pp. 424-432.
 28. J. W. Daly, D. M. Jerina, and B. Witkop, "Arene Oxides and the NIH Shift: The Metabolism, Toxicity and Carcinogenicity of Aromatic Compounds," *Experientia*, Vol. 28 (1972), pp. 1129-1149.

DISCUSSION

DR. JOHN V. MOORE (National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina): Have you done any investigatory work to see what the name of the impurity might be?

DR. ECOBICHON: Not that I know of. I don't even believe Eastman Kodak is aware of it.

TOXICOLOGY OF SELECTED SYMMETRICAL HEXACHLOROBIPHENYL ISOMERS: I. BIOLOGICAL RESPONSES IN CHICKS AND MICE

Marco Blocca, M.D.,* J. A. Moore, D.V.M.,† B. N. Gupta, B.V.Sc., Ph.D.,† and J. D. McKinney, Ph.D.†

Abstract

One-day-old cockerels were fed: (I) 3,10,30,100, and 300 ppm of 3,4,5,3',4',5'-hexachlorobiphenyl (HCB); (II) 400 ppm of 2,3,4,2',3',4'-HCB; (III) 400 ppm of 2,4,5,2',4',5'-HCB; (IV) 400 ppm of 2,3,6,2',3',6'-HCB; and (V) 400 ppm of 2,4,6,2',4',6'-HCB. Surviving chicks were sacrificed at 21 days. Male mice were fed 10, 30, 100 and 300 ppm of three of the above isomers (I, III, V), and survivors were sacrificed at 28 days. HCB's levels in adipose tissue and liver were determined. There were variations among the isomers as to dose and pathologic effects. Isomer (I) showed the greatest effect of those studied on mortality, body weight gain, liver, thymus, and spleen; it also attained the highest tissue concentration. It was the only isomer which produced porphyrin accumulation; and, in the chicks, produced hydropericardium, ascites, and edema. The decreasing order of overall toxicity was I >> V > II, III, IV. A general similarity of response was observed in both chicks and mice.

INTRODUCTION

A number of publications have described various toxicologic effects of commercial polychlorinated biphenyls. The presence of toxic impurities, variable chlorine content, or chlorine substitution patterns make interpretation and comparison of the results of these studies quite difficult.

By comparison, little work has been done on assessing the general toxic effects of single polychlorinated biphenyls. The objective of this report is to describe the first results obtained from a comparative, systematic study of the general biological effects of some hexachlorobiphenyl (HCB) isomers in chicks and mice.

The HCB's were selected because of (1) their predominant presence in higher chlorinated formulations (ref. 1); (2) their relative stability in the environment (particularly their persistence in human tissue) (ref. 1); and (3) their strong inductive effect on several biological parameters (ref. 2). The specific isomers studied were selected as biphenyl models representing different

physicochemical properties. Chicks were used in this experiment because of their high sensitivity to polychlorinated hydrocarbons; mice were selected to confirm results in a mammalian species.

MATERIALS AND METHODS

The experimental protocol is summarized in table 1. The table illustrates the chemicals and dose levels used, the number of animals per dose level, and the duration of the experiment. The HCB's were mixed in a chick edema bioassay diet or a standard powdered mouse diet. The animals were housed in temperature- and humidity-controlled rooms. The chicks were kept in wire-floored cages, the mice in separate plastic cages. Food and water were provided *ad libitum* for the entire experimental period. The animals were observed daily; body weight was recorded twice a week; food consumption was measured once a week for the chicks and three times a week for the mice. Control groups were observed under identical experimental conditions.

Complete necropsies were performed on dead or moribund animals and on the surviving animals at the end of the experimental period. Blood samples were obtained at this time and analyzed for packed cell volume, total serum protein, and protein fractionation. Liver, spleen, and heart weights were recorded for the chicks; in mice, kidneys, right testicle, and adrenals were also weighed. All organs and tissues were examined under UV light for the presence of red fluorescence as an indication of porphyrin accumulation. After fixation, tissues were prepared for histopathologic examination using standard methods.

All animals were assigned to a given dose according to a table of random numbers. Diet, adipose tissue, and liver were collected for HCB's residue analysis.

RESULTS

The complete results of this study are described in a series of papers either in press or in preparation (refs. 3-6). This presentation is a summary comparison of major biological responses observed in chicks and mice. Table 2, which summarizes the chick effects, shows that 3,4,5,3',4',5'-HCB is the most toxic isomer studied, causing death in all the chicks, even at the lowest dose used. You will note that this dose is less than 1/100 of the diet concentrations of the other HCB's. Only one out of ten

*Istituto di Igiene, g. Serravalle, Università di Roma, Città Universitaria, Rome, Italy.

† J. A. Moore, B. N. Gupta, and J. D. McKinney are with the Environmental Biology and Chemistry Branch of the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

chicks died in the 2,3,6,2',3',6'-HCB group; no animals of the other groups died during the experiment. Reduction in body weight gain was observed in all treatment groups.

At the dose levels studied, significant differences in liver weights and histopathologic changes were observed with all HCB isomers. The most toxic was 3,4,5,3',4',5'-HCB, even at the lowest dose. It was the only isomer in which UV fluorescence (porphyrin accumulation) was observed. This finding was quite pronounced, especially in the lining layer of the gizzard, liver, and bones. The slight pathologic effect of the liver observed at 10 ppm is probably due to the very early death of the chicks. The thymus of these chicks was extremely involuted while only slight effect was caused by the other isomers.

Table 3 summarizes the major pathological changes observed: Marked edema of subcutaneous tissue, denoted by gelatinous appearance of subcutaneous fat; marked depletion of lymphocytes in the spleen; diarrhea and soiling of the cloacal area; turbid ascitic fluid; hydropericardium; and loss of visceral fat were findings seen only with the 3,4,5,3',4',5'-HCB. Fatty metamorphosis and single-cell or focal necrosis of the liver, were present, albeit to a variable extent in all animals. In addition, characteristic large black spots, 1 to 5 mm in diameter, were observed under the capsule and on cut surfaces of the liver of birds which received 2,4,6,2',4',6'-HCB. This change was caused by marked dilatation of sinusoids with a result of accumulation of blood. In some cases, the epicardium of chicks fed 2,3,4,2',3',4'-HCB was markedly edematous.

Table 4 summarizes the effects in mice. Again, 3,4,5,3',4',5'-HCB was the most toxic, causing one death at 30 ppm and decreasing body weight gain at the 10-ppm level. Although there were no deaths at 10-ppm level in this experiment, which lasted to the 28th day, in one subsequent experiment, mice fed a diet with 10 ppm died an average of 39.4 days (range 36-47). Only one mouse fed the highest dose (300 ppm) of 2,4,5,2',4',5'-HCB died before the end of the experimental period; in contrast, all mice fed 2,4,6,2',4',6'-HCB at the same level died.

The body weight gain of the mice fed 100 ppm of 2,4,5,2',4',5'-HCB or 2,4,6,2',4',6'-HCB were not significantly reduced. The dose-related increase in liver weight was caused by all three isomers, with the greatest effect being in the 3,4,5,3',4',5'-HCB group. The absence of liver pathology in the mice fed with 300 ppm 3,4,5,3',4',5'-HCB is, again, considered to be related to the early time of death. Only 3,4,5,3',4',5'-HCB caused

porphyrin accumulation and a dramatic atrophy of the lymphatic organs.

The major pathological changes observed in the mice are summarized in table 5. Gelatinous appearance of subcutaneous fat, presence of blood in the gastrointestinal tract, and hemorrhage in the retrobulbar area of the eye were characteristic of the mice that died due to 3,4,5,3',4',5'-HCB toxicity. Accentuation of the hepatic lobules, swelling and hyalinization of the hepatocytes, fatty metamorphosis, and single or focal necrosis were not related to a particular chemical since these changes were observed in all HCB groups to various degrees. Cardiomyopathy and passive congestion of the lung were caused only by 2,4,6,2',4',6'-HCB at the 300-ppm dose.

Retention indices of the mixed liquid phase used for gas chromatography may serve as an index of lipophilicity (table 6). Except for 2,4,6,2',4',6'-HCB, decreasing indices for this isomeric series correlated exactly with decreasing adipose tissue accumulation in chicks. The highest values were shown by 3,4,5,3',4',5'-HCB and 2,3,6,2',3',6'-HCB the lowest. A similar trend in tissue accumulation and retention indices is evident in mice (table 7), but not at all dose levels. A greater concentration of 3,4,5,3',4',5'-HCB was observed in all cases, particularly in the liver.

CONCLUSIONS

There are definite differences in the toxicity of the HCB isomers tested. Comparing toxicity using such biological parameters as mortality, body weight gain, liver effects, porphyrin accumulation, involution of the lymphatic organs, and fluid accumulation in chicks, the decreasing order of overall toxicity would be 3,4,5,3',4',5'-HCB >> 2,4,6,2',4',6'-HCB > 2,4,5,2',4',5'-, 2,3,4,2',3',4'-, 2,3,6,2',3',6'-HCB.

The differences in pathologic effects observed during these experiments were quantitative and, to some degree, qualitative. It is important to note that the nature of the toxicity of 3,4,5,3',4',5'-HCB mimics the effects caused by the dibenzofurans.

Although certain toxicologic characteristics differentiate the biological responses in each species tested, the major toxicopathologic effects were common to both chicks and mice.

REFERENCES

1. S. Jensen and G. Sundstrom, "Structures and Levels of Most Chlorobiphenyls in Two Technical PCB

- Products and in Human Adipose Tissue," *Ambio*, Vol. 3 (1974), pp. 70-75.
2. D. J. Ecobichon and A. M. Comeau, "Isomerically Pure Chlorobiphenyl Congeners and Hepatic Function in the Rat: Influence of Position and Degree of Chlorination," *Toxicol. Appl. Pharmacol.*, Vol. 33 (1975), pp. 94-105.
 3. J. D. McKinney, K. Chae, B. N. Gupta, J. A. Moore, and J. A. Goldstein, "Toxicology of Hexachlorobiphenyl Isomers and 2,3,7,8-Tetrachlorodibenzofuran in Chicks. I. Relationship of Chemical Parameters," *Toxicol. Appl. Pharmacol.*, 1975, in press.
 4. J. A. Goldstein, J. D. McKinney, G. W. Lucier, P. Hickman, H. Bergman, and J. A. Moore, "Toxicology of Hexachlorobiphenyl Isomers and 2,3,7,8-Tetrachlorodibenzofuran in Chicks. II. Effects on Drug Metabolism and Porphyrin Accumulation," *Toxicol. Appl. Pharmacol.*, 1975, in press.
 5. J. D. McKinney, J. R. Hass, and K. Chae, "Metabolism of Pure Hexachlorobiphenyl Isomers in Chicks. Dechlorination, Isomerization, Hydroxylation and Dibenzofuran Formation," 1975, manuscript in preparation.
 6. M. Biocca, K. Chae, B. Gupta, J. McKinney and J. Moore, manuscript in preparation.

Table 1. Protocol for hexachlorobiphenyl isomers toxicity experiments in mice and chicks^a.

Chemical	Dose level (ppm)		No. of animals/ dose level		Experimental period (day)	
	Mice	Chicks	Mice	Chicks	Mice	Chicks
(>99 percent purity)						
3,4,5,3',4',5'-HCB	3	3	5	10	28	21
	10	10				
	30	30				
	100	100				
	300	300				
2,3,4,2',3',4'-HCB	-	400	-	10	-	21
2,4,5,2',4',5'-HCB	10	400	5	10	28	21
	30					
	100					
	300					
2,3,6,2',3',5'-HCB	-	400	-	10	-	21
2,4,6,2',4',6'-HCB	10	400	5	10	28	21
	30					
	100					
	300					

^aFive-week old C57BL/6 male mice; 1-day-old white leghorn cockerels.

Table 2. Summary of the biological effects of hexachlorobiphenyl isomers in chicks

Chemical	Dose level (ppm)	Mortality	Body weight gain (% of control)	Liver effect	Porphyrin Accumulation	Thymus effect
3,4,5,3',4',5'-HCB	3	10/10	-	+++	-	+++
	10	10/10	-	++	+++	+++
2,3,4,2',3',4'-HCB	400	0/8	68	++	-	+
2,4,5,2',4',5'-HCB	400	0/10	66	++	-	+
2,3,6,2',3',6'-HCB	400	1/10	80	++	-	+
2,4,6,2',4',6'-HCB	400	0/10	83	+++	-	+

Table 3. Summary of major pathological changes in chicks given different hexachlorobiphenyl isomers for 21 days

Chemical	Dose level (ppm)	Liver	Thymus	Spleen	Fluid Accumulation
3,4,5,3',4',5'-HCB	3	Marked; fatty metamorphosis, focal necrosis.	Marked; involution.	Marked; depletion of lymphocytes.	Subcutaneous edema, ascites, hydropericardium.
2,3,4,2',3',4'-HCB	400	Moderate; hyalinization, single-cell necrosis.	Slight; involution.	NS ^a	Epicardial edema.
2,4,5,2',4',5'-HCB	400	Moderate; single-cell necrosis.	Slight; involution.	NS ^a	NS ^a
2,3,6,2',3',6'-HCB	400	Moderate; fatty metamorphosis, focal necrosis, giant cell formation.	Slight; involution.	NS ^a	NS ^a
2,4,6,2',4',6'-HCB	400	Marked; fatty metamorphosis, focal necrosis, giant cell formation, marked focal dilatation of sinusoids.	Slight; involution.	NS ^a	NS ^a

^aNS = not significant.

Table 4. Summary of the biological effects of hexachlorobiphenyl isomers in mice

Chemical	Dose level (ppm)	Mortality	Body weight gain (% of control)	Liver effect	Porphyryn Accumulation	Thymus effect
3,4,5,3',4',5'-HCB	10	0/5	12	++	+	++
	100	3/5	-	+++	+++	+++
	300	5/5	-	-	-	+++
2,4,5,2',4',5'-HCB	100	0/5	91	+	-	-
	300	1/5	58	++	-	+
2,4,6,2',4',6'-HCB	100	0/5	85	+	-	-
	300	5/5	-	++	-	++

Table 5. Summary of major pathological changes in mice given different hexachlorobiphenyl isomers for 28 days

Chemical	Dose level (ppm)	Liver	Thymus	Spleen	Heart
3,4,5,3',4',5'-HCB	30	Marked; fatty metamorphosis, single-cell necrosis.	Marked; involution.	Moderate; depletion of lymphocytes.	NS ^a
2,4,5,2',4',5'-HCB	300	Slight; swelling of hepatocytes.	Slight; involution.	NS ^a	NS ^a
2,4,6,2',4',6'-HCB	300	Marked; fatty metamorphosis, single-cell necrosis.	Marked; involution.	Moderate; depletion of lymphocytes.	Moderate; cardiomyopathy.

^aNS = not significant.

Table 6. Gas chromatographic retention indices and tissue hexachlorobiphenyl levels in chicks

Chemical	Dose level (ppm)	GC retention index value	Concentration (ppm)	
			Adipose T.	Liver
3,4,5,3',4',5'-HCB	100	2,820	1,210	-
	300		4,912	
2,3,4,2',3',4'-HCB	400	2,678	3,998	44
2,4,5,2',4',5'-HCB	400	2,542	3,921	59
2,3,6,2',3',6'-HCB	400	2,478	2,893	9
2,4,6,2',4',6'-HCB	400	2,346	4,172	24

Table 7. Gas chromatographic retention indices and tissue hexachlorobiphenyl levels in mice

Chemical	Dose level (ppm)	GC retention index value	Concentration (ppm)	
			Adipose T.	Liver
3,4,5,3',4',5'-HCB	10	2820	508	95
	30		1,383	498
	100		2,278	887
	300		6,912	1,344
2,4,5,2',4',5'-HCB	10	2542	296	7
	30		416	30
	100		1,864	83
	300		3,923	637
2,4,6,2',4',6'-HCB	10	2346	99	6
	30		582	15
	100		1,402	122
	300		4,329	1,022

TOXICOLOGY OF SELECTED SYMMETRICAL HEXACHLOROBIPHENYL ISOMERS: CORRELATING BIOLOGICAL EFFECTS WITH CHEMICAL STRUCTURE

James D. McKinney, Ph.D.*

Abstract

The symmetrical hexachlorobiphenyls (HCB's) represent model PCB's with high and constant chlorine content permitting unequivocal study of a given substitution pattern. These isomers show separate and distinct biological responses which can be related to chemical structure via effects of varying chlorine substitution on compound lipophilicity and metabolism. Compound purity must also be assured. Relative molecular polarizability can be correlated with lipophilicity and biological activity and is measurable by chromatographic and spectroscopic techniques. These parameters were highest in HCB's with planar symmetry and 4,4'-substitution. The rates of metabolism of these isomers are considered of lesser importance than the potentially highly toxic nature of some of the intermediary and terminal metabolites.

INTRODUCTION

A previous paper (ref. 1) has shown the importance of the degree of chlorination of PCB's in terms of their distribution and excretion in the rat. Of particular concern is the implication that not more than 20 percent of the hexachlorobiphenyl isomer studied would ever be excreted. Therefore, hexachlorobiphenyls may represent PCB's with both high chlorine content and biological half life. Our studies with symmetrical hexachlorobiphenyl isomers (HCB's) sought to determine the varying biological effects of HCB's as a function of their varying substitution patterns (figure 1). Two of the isomers studied are found in about 3 to 4 percent (area percent by flame ionization gas chromatography) in Aroclors 1254 and 1260. Several major components of these same Aroclors contain various combinations of the substitution patterns studied. Since the effects of chlorine substitution in biphenyls on spectral and chromatographic properties may be approximately predicted (refs. 2,3) using additive parameters obtained from chlorobenzenes, it may be possible to predict the biological behavior of the various combinations through study of the appropriate individual symmetrical isomers.

*J. D. McKinney is with the Environmental Biology and Chemistry Branch of the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

TOXICOLOGICALLY SIGNIFICANT PROPERTIES

As previously described (ref. 4), our studies with both chickens and mice have shown separate and distinct biological effects at submaximal doses for the different isomers even though all of these isomers might be considered potent (relative to lower chlorinated isomers). In explaining these differences, we feel that the three major considerations are compound purity, lipophilicity, and metabolism. Intestinal adsorption was not considered since earlier work (ref. 5) failed to show appreciable differences for various PCB's.

Compound purity can be very important since both the individual synthetic isomers (ref. 6) and the Aroclor mixtures are known (ref. 7) to be contaminated with small amounts of chlorinated dibenzofurans which, in some species at least, are orders of magnitude more toxic than the PCB's. Since separate and distinct differences in the biological effects of 2,3,7,8-tetrachlorodibenzofuran and the HCB's were found in our work (refs. 8,9), one may be in a position to assess the involvement of dibenzofurans as contaminants and, as will be described later, as potential metabolites.

Relatively little work (ref. 10) has been done associating the effects of varying PCB structure with varying degrees of tissue accumulation. Our work (ref. 8) does appear to show a trend in adipose tissue accumulation of HCB's which correlated with molecular polarizability as measured by chromatographic and spectroscopic techniques. The HCB gas-chromatographic (GC) retention indices (increasing) generally correlated with their overall biological response and were highest in isomers with 3,4-substitution. The amount of HCB in the adipose tissue does not determine activity, but its distribution in this tissue and activity in the liver may both reflect lipophilicity. Since the GC retention index correlation is consistent with a number and variety of GC columns, it is possible that it may have some value in predicting lipophilicity. The lipophilicity in turn relates to biological activity through effective tissue concentration of a given HCB. The differences in adipose tissue accumulation do not appear to be a function of metabolic removal since the least accumulated isomer (2,3,6,2',3',6') was one of the least metabolized (ref. 11).

Considerations of metabolism must take into account the differences in rates of degradation and excretion as well as the nature of intermediary and terminal metabolites. Higher degradation rates (shorter biological